0001569329 Youngevity International,
Inc. false --12-31 Q2 2020 0.001 0.001 5,000,000 5,000,000 8 8
161,135 161,135 161,135 161,135 5 5 0 0 129,332 129,332 9.75 9.75
590,273 590,273 578,898 578,898 0.001 0.001 50,000,000 50,000,000
32,216,599 32,216,599 30,274,601 30,274,601 469 500,000 7,871,000
4,700,000 5 25 75 3 76,924 116,655 3 25,000 0 0 0 7,871,000
1,649,000 5,000,000 4 4 4 2 2,000,000 5 6.00 6.00 8.00 8.00 5
25,000 3 3 5 3 448,420 4 631,579 4 4 150,000 161,135 0.1 6,098 4
257,000 3 3 7,871,000 2 Assets held for sale at June 30, 2020
consisted of approximately $1,053,000 in land and $443,000 in
computer equipment related to the commercial hemp segment. (See
Note 13) Interest on lease liabilities are classified within
interest expense, net. Amortization of leased assets are classified
as a component of depreciation and amortization. Finance lease
right-of-use assets are recorded within property and equipment, net
of accumulated amortization of approximately $1,759,000 and
$1,367,000 at June 30, 2020 and December 31, 2019, respectively
Operating lease costs are classified within selling and marketing
and general and administrative expenses.
00015693292020-01-012020-06-30 xbrli:shares 00015693292022-06-17
thunderdome:item iso4217:USD 00015693292020-06-30
00015693292019-12-31
0001569329ygyi:NotesPayableExcludingConvertibleNotesPayableMember2020-06-30
0001569329ygyi:NotesPayableExcludingConvertibleNotesPayableMember2019-12-31
iso4217:USDxbrli:shares xbrli:pure
0001569329ygyi:SeriesAConvertiblePreferredStockMember2020-01-012020-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMember2019-01-012019-12-31
0001569329ygyi:SeriesAConvertiblePreferredStockMember2020-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMember2019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2020-01-012020-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMember2019-01-012019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2020-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMember2019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2020-01-012020-06-30
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-01-012019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2020-06-30
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-12-31
00015693292020-04-012020-06-30 00015693292019-04-012019-06-30
00015693292019-01-012019-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-03-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-03-31
0001569329us-gaap:CommonStockMember2020-03-31
0001569329us-gaap:AdditionalPaidInCapitalMember2020-03-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-31
0001569329us-gaap:RetainedEarningsMember2020-03-31
00015693292020-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-04-012020-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-04-012020-06-30
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-04-012020-06-30
0001569329us-gaap:CommonStockMember2020-04-012020-06-30
0001569329us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-30
0001569329us-gaap:RetainedEarningsMember2020-04-012020-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-04-012020-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-04-012020-06-30
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-04-012020-06-30
0001569329us-gaap:CommonStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-04-012020-06-30
0001569329us-gaap:AdditionalPaidInCapitalMemberygyi:SharesWithHempJointVentureAgreementMember2020-04-012020-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberygyi:SharesWithHempJointVentureAgreementMember2020-04-012020-06-30
0001569329us-gaap:RetainedEarningsMemberygyi:SharesWithHempJointVentureAgreementMember2020-04-012020-06-30
0001569329ygyi:SharesWithHempJointVentureAgreementMember2020-04-012020-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-06-30
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-06-30
0001569329us-gaap:CommonStockMember2020-06-30
0001569329us-gaap:AdditionalPaidInCapitalMember2020-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-30
0001569329us-gaap:RetainedEarningsMember2020-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-12-31
0001569329us-gaap:CommonStockMember2019-12-31
0001569329us-gaap:AdditionalPaidInCapitalMember2019-12-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31
0001569329us-gaap:RetainedEarningsMember2019-12-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-06-30
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-06-30
0001569329us-gaap:CommonStockMember2020-01-012020-06-30
0001569329us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-30
0001569329us-gaap:RetainedEarningsMember2020-01-012020-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-06-30
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-06-30
0001569329us-gaap:CommonStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-06-30
0001569329us-gaap:AdditionalPaidInCapitalMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-06-30
0001569329us-gaap:RetainedEarningsMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-06-30
0001569329ygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-06-30
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-06-30
0001569329us-gaap:CommonStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-06-30
0001569329us-gaap:AdditionalPaidInCapitalMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-06-30
0001569329us-gaap:RetainedEarningsMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-06-30
0001569329ygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-03-31
0001569329us-gaap:CommonStockMember2019-03-31
0001569329us-gaap:AdditionalPaidInCapitalMember2019-03-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-31
0001569329us-gaap:RetainedEarningsMember2019-03-31
00015693292019-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-04-012019-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-04-012019-06-30
0001569329us-gaap:CommonStockMember2019-04-012019-06-30
0001569329us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-30
0001569329us-gaap:RetainedEarningsMember2019-04-012019-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2019-04-012019-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2019-04-012019-06-30
0001569329us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2019-04-012019-06-30
0001569329us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2019-04-012019-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:PrivatePlacementMember2019-04-012019-06-30
0001569329us-gaap:RetainedEarningsMemberus-gaap:PrivatePlacementMember2019-04-012019-06-30
0001569329us-gaap:PrivatePlacementMember2019-04-012019-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-06-30
0001569329us-gaap:CommonStockMember2019-06-30
0001569329us-gaap:AdditionalPaidInCapitalMember2019-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-30
0001569329us-gaap:RetainedEarningsMember2019-06-30
00015693292019-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2018-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2018-12-31
0001569329us-gaap:CommonStockMember2018-12-31
0001569329us-gaap:AdditionalPaidInCapitalMember2018-12-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-31
0001569329us-gaap:RetainedEarningsMember2018-12-31
00015693292018-12-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-06-30
0001569329us-gaap:CommonStockMember2019-01-012019-06-30
0001569329us-gaap:AdditionalPaidInCapitalMember2019-01-012019-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-06-30
0001569329us-gaap:RetainedEarningsMember2019-01-012019-06-30
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2019-01-012019-06-30
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2019-01-012019-06-30
0001569329us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2019-01-012019-06-30
0001569329us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2019-01-012019-06-30
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:PrivatePlacementMember2019-01-012019-06-30
0001569329us-gaap:RetainedEarningsMemberus-gaap:PrivatePlacementMember2019-01-012019-06-30
0001569329us-gaap:PrivatePlacementMember2019-01-012019-06-30
0001569329us-gaap:LandMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-06-30
0001569329us-gaap:LandMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-06-30
0001569329us-gaap:LandMemberus-gaap:CommonStockMember2019-01-012019-06-30
0001569329us-gaap:LandMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-06-30
0001569329us-gaap:LandMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-06-30
0001569329us-gaap:LandMemberus-gaap:RetainedEarningsMember2019-01-012019-06-30
0001569329us-gaap:LandMember2019-01-012019-06-30
0001569329us-gaap:TrademarksMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-06-30
0001569329us-gaap:TrademarksMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-06-30
0001569329us-gaap:TrademarksMemberus-gaap:CommonStockMember2019-01-012019-06-30
0001569329us-gaap:TrademarksMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-06-30
0001569329us-gaap:TrademarksMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-06-30
0001569329us-gaap:TrademarksMemberus-gaap:RetainedEarningsMember2019-01-012019-06-30
0001569329us-gaap:TrademarksMember2019-01-012019-06-30
0001569329ygyi:PromissoryNotesMember2020-01-012020-06-30
0001569329ygyi:PromissoryNotesMember2019-01-012019-06-30
0001569329ygyi:PropertyAndEquipmentFundedByFinancingLeasingAgreementMember2020-01-012020-06-30
0001569329ygyi:PropertyAndEquipmentFundedByFinancingLeasingAgreementMember2019-01-012019-06-30
0001569329ygyi:PropertyAndEquipmentFundedByMortgageAgreementMember2020-01-012020-06-30
0001569329ygyi:PropertyAndEquipmentFundedByMortgageAgreementMember2019-01-012019-06-30
0001569329ygyi:StockForNicaHempProjectMember2020-01-012020-06-30
0001569329ygyi:StockForNicaHempProjectMember2019-01-012019-06-30
0001569329ygyi:CommonStockForPromissoryNoteFinancingMember2020-01-012020-06-30
0001569329ygyi:CommonStockForPromissoryNoteFinancingMember2019-01-012019-06-30
0001569329ygyi:StockForPropertyAndEquipmentMember2020-01-012020-06-30
0001569329ygyi:StockForPropertyAndEquipmentMember2019-01-012019-06-30
0001569329ygyi:StockForPurchaseOfIntangiblesMember2020-01-012020-06-30
0001569329ygyi:StockForPurchaseOfIntangiblesMember2019-01-012019-06-30
0001569329ygyi:StockForNoteReceivablesMember2020-01-012020-06-30
0001569329ygyi:StockForNoteReceivablesMember2019-01-012019-06-30
0001569329ygyi:StockInConnectionWithAcquisitionMember2020-01-012020-06-30
0001569329ygyi:StockInConnectionWithAcquisitionMember2019-01-012019-06-30
0001569329ygyi:DirectSellingSegmentMember2020-04-012020-06-30
0001569329ygyi:CommercialCoffeeSegmentMember2020-04-012020-06-30
0001569329ygyi:CommercialHempSegmentMember2020-04-012020-06-30
0001569329ygyi:DirectSellingSegmentMember2019-04-012019-06-30
0001569329ygyi:CommercialCoffeeSegmentMember2019-04-012019-06-30
0001569329ygyi:CommercialHempSegmentMember2019-04-012019-06-30
0001569329ygyi:DirectSellingSegmentMember2020-01-012020-06-30
0001569329ygyi:CommercialCoffeeSegmentMember2020-01-012020-06-30
0001569329ygyi:CommercialHempSegmentMember2020-01-012020-06-30
0001569329ygyi:DirectSellingSegmentMember2019-01-012019-06-30
0001569329ygyi:CommercialCoffeeSegmentMember2019-01-012019-06-30
0001569329ygyi:CommercialHempSegmentMember2019-01-012019-06-30
utr:acre 0001569329ygyi:CoffeePlantationMember2020-06-30
0001569329ygyi:DryprocessingFacilityMember2020-06-30
0001569329us-gaap:WarrantMember2020-01-012020-06-30
0001569329us-gaap:WarrantMember2019-01-012019-06-30
0001569329ygyi:PreferredStockConversionsMember2020-01-012020-06-30
0001569329ygyi:PreferredStockConversionsMember2019-01-012019-06-30
0001569329ygyi:PrincipalConversionOnConvertibleNotesMember2020-01-012020-06-30
0001569329ygyi:PrincipalConversionOnConvertibleNotesMember2019-01-012019-06-30
0001569329us-gaap:EmployeeStockOptionMember2020-01-012020-06-30
0001569329us-gaap:EmployeeStockOptionMember2019-01-012019-06-30
0001569329us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-30
0001569329us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-06-30
0001569329ygyi:BeneyouMembersrt:MaximumMember2019-11-012019-11-01
0001569329ygyi:BeneyouMember2019-11-012019-11-01
0001569329ygyi:BeneyouMember2019-11-01
0001569329ygyi:BeneyouMemberus-gaap:TrademarksAndTradeNamesMember2019-11-01
0001569329ygyi:BeneyouMemberygyi:DistributorOrganizationMember2019-11-01
0001569329ygyi:BeneyouMemberus-gaap:CustomerRelationshipsMember2019-11-01
0001569329ygyi:BeneyouMemberus-gaap:NoncompeteAgreementsMember2019-11-01
utr:Y
0001569329ygyi:BeneyouMemberus-gaap:TrademarksAndTradeNamesMember2019-11-012019-11-01
0001569329ygyi:BeneyouMemberygyi:DistributorOrganizationMember2019-11-012019-11-01
0001569329ygyi:BeneyouMemberus-gaap:CustomerRelationshipsMember2019-11-012019-11-01
0001569329ygyi:BeneyouMemberus-gaap:NoncompeteAgreementsMember2019-11-012019-11-01
0001569329ygyi:AepaWithKhrysosGlobalMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:CommonStockMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-02-132019-12-31
0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-12-312019-12-31
0001569329ygyi:AccruedExpensesMemberygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2020-06-30
0001569329ygyi:AccruedExpensesMemberygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-12-31
0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ContingentConsiderationPayableInCashMember2019-02-122019-02-12
0001569329ygyi:KhrysosGlobalMember2019-02-12
0001569329ygyi:KhrysosGlobalMemberus-gaap:TrademarksAndTradeNamesMember2019-02-12
0001569329ygyi:KhrysosGlobalMemberus-gaap:CustomerRelationshipsMember2019-02-12
0001569329ygyi:KhrysosGlobalMemberus-gaap:NoncompeteAgreementsMember2019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMember2019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:TrademarksAndTradeNamesMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:CustomerRelationshipsMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:NoncompeteAgreementsMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMember2019-12-31
0001569329ygyi:CLRMemberygyi:HhMember2020-04-012020-06-30
0001569329ygyi:CLRMemberygyi:HhMember2020-01-012020-06-30
0001569329ygyi:CLRMemberygyi:HhExportMember2020-04-012020-06-30
0001569329ygyi:CLRMemberygyi:HhExportMember2020-01-012020-06-30
0001569329ygyi:CLRMemberygyi:HhExportMember2019-04-012019-06-30
0001569329ygyi:CLRMemberygyi:HhExportMember2019-01-012019-06-30
0001569329ygyi:CustomerRelatedRevenueReceivablesMemberygyi:CLRMemberygyi:HhExportMember2020-06-30
0001569329ygyi:CustomerRelatedRevenueReceivablesMemberygyi:CLRMemberygyi:HhExportMember2019-12-31
0001569329ygyi:CLRMemberygyi:HhExportMember2019-01-012019-12-31
0001569329ygyi:CLRMemberygyi:GreenCoffeeAcquisitionMemberygyi:HhMember2020-06-30
0001569329ygyi:CLRMemberygyi:BillingForFreightAndOtherChargesMemberygyi:HhMember2020-06-30
0001569329ygyi:CLRMemberygyi:MillOperationCostMemberygyi:HhMember2020-06-30
0001569329ygyi:CLRMemberygyi:GreenCoffeeSoldButNotDeliveredMemberygyi:HhMember2020-06-30
0001569329ygyi:NicaraguanAgencyMemberygyi:HhExportGroupMember2020-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2020-03-31
iso4217:USDutr:lb
0001569329ygyi:CLRMemberygyi:HhExportMember2020-01-012020-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2018-12-31
0001569329ygyi:CLRMemberygyi:HhExportMember2019-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2019-03-012019-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2020-06-30
0001569329ygyi:CLRMemberygyi:HhExportMember2019-12-31
0001569329ygyi:CLRMemberygyi:MatagalpaPropertyMemberygyi:NicaraguanPartnerMember2019-01-31
0001569329ygyi:NicaraguanPartnerMember2019-01-31
0001569329ygyi:CLRMember2019-01-31
0001569329ygyi:HhExportMember2019-01-012019-01-31
0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2020-04-012020-06-30
0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2020-01-012020-06-30
0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2019-04-012019-06-30
0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2019-01-012019-06-30
0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2019-01-012020-06-30
0001569329ygyi:CLRMemberygyi:OperatingEquipmentMember2019-01-012020-06-30
0001569329ygyi:NicaraguanPartnerMemberygyi:ConstructionOfMatagalpaMillProjectMember2019-01-012020-06-30
0001569329ygyi:HhExportMember2020-01-012020-06-30
0001569329ygyi:HhExportMember2019-01-012019-12-31
0001569329srt:ScenarioForecastMemberygyi:SharesWithHempJointVentureAgreementMember2020-07-012020-07-31
0001569329ygyi:WarrantsWithHempJointVentureAgreementMembersrt:ScenarioForecastMember2020-07-31
0001569329ygyi:NicaraguanJvPartnersMembersrt:ScenarioForecastMember2020-07-31
0001569329ygyi:UsPartnersMembersrt:ScenarioForecastMember2020-07-31
0001569329ygyi:CLRMemberygyi:HhExportMemberygyi:SharesIssuedForPurchaseConsiderationMember2019-01-012019-01-31
0001569329ygyi:CLRMemberygyi:HhExportMemberygyi:SharesIssuedForPurchaseConsiderationMember2019-01-31
0001569329ygyi:CLRMemberygyi:MrHernandezMember2017-05-31
0001569329ygyi:WvnpMember2020-01-012020-03-31
0001569329ygyi:WvnpMember2019-01-012019-03-31
0001569329ygyi:WvnpMember2019-01-012019-06-30
0001569329ygyi:DistributorCommissionMemberygyi:RichardRentonMember2020-01-012020-03-31
0001569329ygyi:CreditNoteMemberygyi:MrGroverMember2020-06-30
0001569329ygyi:CreditNoteMemberygyi:MrGroverMember2019-12-31
0001569329ygyi:MrGroverMemberygyi:WarrantsWith2014ConvertibleNoteMember2019-07-012019-07-31
0001569329ygyi:MrGroverMemberygyi:WarrantsWith2014ConvertibleNoteMember2019-06-30
0001569329ygyi:MrGroverMemberygyi:WarrantsWith2014ConvertibleNoteMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:ConversionOf2014ConvertibleNoteIntoCommonStockMemberygyi:PaulSallwasserMember2020-01-012020-06-30
0001569329ygyi:WarrantsWith2014PrivatePlacementMemberygyi:PaulSallwasserMember2020-06-30
0001569329ygyi:ConversionOf2017ConvertiblePrivatePlacementNoteIntoCommonStockMemberygyi:PaulSallwasserMember2020-01-012020-06-30
0001569329ygyi:WarrantsWith2017PrivatePlacementMemberygyi:PaulSallwasserMember2020-06-30
0001569329ygyi:ConversionOf2017ConvertibleNoteIntoCommonStockMemberygyi:PaulSallwasserMember2020-01-012020-06-30
0001569329ygyi:WarrantsWith2017ConvertibleNoteMemberygyi:PaulSallwasserMember2020-06-30
0001569329ygyi:ConversionOf2017ConvertibleNoteIntoCommonStockMemberygyi:PaulSallwasserMember2018-03-012018-03-31
0001569329ygyi:WarrantsWith2017ConvertibleNoteMemberygyi:PaulSallwasserMember2018-03-31
0001569329ygyi:PaulSallwasserMember2019-08-012019-08-31
0001569329ygyi:PaulSallwasserMember2020-06-30
0001569329ygyi:PaulSallwasserMember2019-06-30
0001569329ygyi:MrDanielManglessMember2019-02-012019-02-28
0001569329ygyi:MrDanielManglessMember2019-02-28
0001569329ygyi:MrDanielManglessMember2019-06-012019-06-30
0001569329ygyi:MrDanielManglessMember2019-06-30
0001569329ygyi:MrDanielManglessMember2020-03-31
0001569329ygyi:MrDanielManglessMember2020-03-012020-03-31
0001569329ygyi:MrDanielManglessMembersrt:ScenarioForecastMember2021-04-012021-04-30
0001569329ygyi:JjeEquipmentMember2020-06-30
0001569329ygyi:JjeEquipmentMember2019-12-31
0001569329ygyi:YoungevityBeTheChangeFoundationMember2020-04-012020-06-30
0001569329ygyi:YoungevityBeTheChangeFoundationMember2019-04-012019-06-30
0001569329ygyi:YoungevityBeTheChangeFoundationMember2020-01-012020-06-30
0001569329ygyi:YoungevityBeTheChangeFoundationMember2019-01-012019-06-30
0001569329ygyi:CurrentLiabilitiesMemberygyi:YoungevityBeTheChangeFoundationMember2020-06-30
0001569329ygyi:CurrentLiabilitiesMemberygyi:YoungevityBeTheChangeFoundationMember2019-12-31
0001569329ygyi:PrivatePlacement2014Memberygyi:DanielBriskieAndMaidaBriskieMember2014-09-30
0001569329ygyi:PrivatePlacement2014Memberygyi:DanielBriskieAndMaidaBriskieMember2020-06-30
0001569329ygyi:PrivatePlacement2014Memberygyi:DanielBriskieAndMaidaBriskieMember2019-12-31
0001569329ygyi:PrivatePlacement2014Memberygyi:DouglasBriskieMember2014-08-31
0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2020-04-012020-06-30
0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2019-04-012019-06-30
0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-06-30
0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-06-30
0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2020-04-012020-06-30
0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2019-04-012019-06-30
0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-06-30
0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-06-30
0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2020-04-012020-06-30
0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2019-04-012019-06-30
0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-06-30
0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-06-30
0001569329ygyi:CustomerDepositsMember2020-06-30
0001569329ygyi:CustomerDepositsMember2019-12-31
0001569329ygyi:RewardsProgramMember2020-06-30
0001569329ygyi:HeritageMakersMember2020-06-30
0001569329ygyi:HeritageMakersMember2019-12-31
0001569329ygyi:ConventionAndDistributorEventsMember2020-06-30
0001569329ygyi:ConventionAndDistributorEventsMember2019-12-31
0001569329ygyi:CommercialCoffeeSegmentMember2020-06-30
0001569329ygyi:CommercialCoffeeSegmentMember2019-12-31
0001569329ygyi:CommercialHempSegmentMember2020-06-30
0001569329ygyi:CommercialHempSegmentMember2019-12-31
0001569329ygyi:HeritageMakersMember2020-04-012020-06-30
0001569329ygyi:HeritageMakersMember2020-01-012020-06-30
0001569329ygyi:HhExportMember2019-12-31
0001569329ygyi:HhExportMember2020-01-012020-06-30
0001569329ygyi:HhExportMember2019-01-012019-12-31
0001569329us-gaap:BuildingMember2020-06-30
0001569329us-gaap:BuildingMember2019-12-31
0001569329us-gaap:LeaseholdImprovementsMember2020-06-30
0001569329us-gaap:LeaseholdImprovementsMember2019-12-31
0001569329us-gaap:LandMember2020-06-30
0001569329us-gaap:LandMember2019-12-31
0001569329us-gaap:LandImprovementsMember2020-06-30
0001569329us-gaap:LandImprovementsMember2019-12-31
0001569329ygyi:ProducingCoffeeTreesMember2020-06-30
0001569329ygyi:ProducingCoffeeTreesMember2019-12-31
0001569329ygyi:ManufacturingEquipmentMember2020-06-30
0001569329ygyi:ManufacturingEquipmentMember2019-12-31
0001569329ygyi:FurnitureAndOtherEquipmentMember2020-06-30
0001569329ygyi:FurnitureAndOtherEquipmentMember2019-12-31
0001569329ygyi:ComputerSoftwareMember2020-06-30
0001569329ygyi:ComputerSoftwareMember2019-12-31
0001569329us-gaap:ComputerEquipmentMember2020-06-30
0001569329us-gaap:ComputerEquipmentMember2019-12-31
0001569329us-gaap:VehiclesMember2020-06-30
0001569329us-gaap:VehiclesMember2019-12-31
0001569329ygyi:AssetsHeldForSaleMember2020-06-30
0001569329ygyi:AssetsHeldForSaleMember2019-12-31
0001569329us-gaap:ConstructionInProgressMember2020-06-30
0001569329us-gaap:ConstructionInProgressMember2019-12-31
0001569329us-gaap:LandMember2020-06-30
0001569329us-gaap:ComputerEquipmentMemberygyi:CommercialHempSegmentMember2020-06-30
0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2020-04-012020-06-30
0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2019-04-012019-06-30
0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2020-01-012020-06-30
0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2019-01-012019-06-30
0001569329ygyi:DepreciationAndAmortizationMember2020-04-012020-06-30
0001569329ygyi:DepreciationAndAmortizationMember2019-04-012019-06-30
0001569329ygyi:DepreciationAndAmortizationMember2020-01-012020-06-30
0001569329ygyi:DepreciationAndAmortizationMember2019-01-012019-06-30
0001569329us-gaap:InterestExpenseMember2020-04-012020-06-30
0001569329us-gaap:InterestExpenseMember2019-04-012019-06-30
0001569329us-gaap:InterestExpenseMember2020-01-012020-06-30
0001569329us-gaap:InterestExpenseMember2019-01-012019-06-30
0001569329ygyi:DistributorOrganizationMember2020-06-30
0001569329ygyi:DistributorOrganizationMember2019-12-31
0001569329us-gaap:TrademarksAndTradeNamesMember2020-06-30
0001569329us-gaap:TrademarksAndTradeNamesMember2019-12-31
0001569329us-gaap:CustomerRelationshipsMember2020-06-30
0001569329us-gaap:CustomerRelationshipsMember2019-12-31
0001569329ygyi:InternallyDevelopedSoftwareMember2020-06-30
0001569329ygyi:InternallyDevelopedSoftwareMember2019-12-31
0001569329us-gaap:NoncompeteAgreementsMember2020-06-30
0001569329us-gaap:NoncompeteAgreementsMember2019-12-31
0001569329us-gaap:TrademarksMember2020-06-30
0001569329us-gaap:TrademarksMember2019-12-31
0001569329ygyi:DirectSellingSegmentMember2020-06-30
0001569329ygyi:DirectSellingSegmentMember2019-12-31
0001569329ygyi:CLRMemberygyi:CreditNoteMember2018-12-31
0001569329ygyi:CLRMemberygyi:CreditNoteMember2019-12-31
0001569329ygyi:CLRMemberygyi:CreditNoteMember2020-06-30
0001569329ygyi:WarrantWithCreditNotesOneMember2018-12-31
0001569329ygyi:WarrantsWithCreditNotesTwoMember2018-12-31
0001569329ygyi:CreditNoteMember2018-12-31
0001569329ygyi:CreditNotesWarrantsWithAdvisoryAgreementMember2018-12-31
0001569329ygyi:CreditNoteMember2020-04-012020-06-30
0001569329ygyi:CreditNoteMember2019-04-012019-06-30
0001569329ygyi:CreditNoteMember2020-01-012020-06-30
0001569329ygyi:CreditNoteMember2019-01-012019-06-30
0001569329ygyi:CreditNoteMember2020-06-30
0001569329ygyi:CreditNoteMember2019-12-31
0001569329ygyi:PromissoryNotes2019Member2019-03-012019-03-31
0001569329ygyi:PromissoryNotes2019Member2019-03-31
0001569329ygyi:PromissoryNotes2019Member2020-06-30
0001569329ygyi:PromissoryNotes2019Member2019-12-31
0001569329ygyi:SharesInConnectionWithPromissoryNotes2019Member2019-03-012019-03-31
0001569329ygyi:WarrantsInConnectionWithPromissoryNotes2019Member2019-03-31
0001569329ygyi:PromissoryNotes2019Member2020-04-012020-06-30
0001569329ygyi:PromissoryNotes2019Member2019-04-012019-06-30
0001569329ygyi:PromissoryNotes2019Member2020-01-012020-06-30
0001569329ygyi:PromissoryNotes2019Member2019-01-012019-06-30
0001569329ygyi:ManglessNoteMember2020-03-31
0001569329ygyi:StockInConnectionWithManglessNoteMember2020-03-012020-03-31
0001569329ygyi:ManglessNoteMember2020-04-012020-06-30
0001569329ygyi:ManglessNoteMember2020-01-012020-06-30
0001569329ygyi:ManglessNoteMember2020-06-30
0001569329srt:ScenarioForecastMemberygyi:StockInConnectionWithManglessNoteMember2021-04-012021-04-30
0001569329ygyi:BoswellMortgageNote2400Member2013-12-31
0001569329ygyi:BoswellMortgageNote2400Member2013-01-012013-12-31
0001569329ygyi:BoswellMortgageNote2400Memberus-gaap:PrimeRateMember2013-01-012013-12-31
0001569329ygyi:BoswellMortgageNote2400Member2020-01-012020-06-30
0001569329ygyi:BoswellMortgageNote2400Member2019-01-012019-12-31
0001569329ygyi:BoswellMortgageNote2400Member2020-06-30
0001569329ygyi:BoswellMortgageNote2400Member2019-12-31
0001569329ygyi:KhrysosMortgageNotesForPropertiesInClemontFloridaMember2020-03-31
0001569329ygyi:KhrysosMortgageNotesForPropertiesInMascotteFloridaMember2020-03-31
0001569329ygyi:KhrysosMortgageNotesForPropertiesInMascotteFloridaMember2020-06-30
0001569329ygyi:KhrysosMortgageNotesForPropertiesInMascotteFloridaMember2019-12-31
0001569329ygyi:LandInGrovelandFloridaMember2019-02-28
0001569329ygyi:LandInGrovelandFloridaMember2019-02-012019-02-28
0001569329ygyi:MortgageWithLandAcquisitionInGrovelandFloridaMember2019-02-28
0001569329ygyi:MortgageWithLandAcquisitionInGrovelandFloridaMember2020-06-30
0001569329ygyi:MortgageWithLandAcquisitionInGrovelandFloridaMember2019-12-31
0001569329ygyi:M2cPurchaseAgreementMember2007-03-012007-03-31
0001569329ygyi:M2cPurchaseAgreementMember2007-03-31
0001569329ygyi:M2cPurchaseAgreementMember2020-06-30
0001569329ygyi:M2cPurchaseAgreementMember2019-12-31
00015693292020-04-012020-04-30
0001569329ygyi:DirectSellingSegmentMember2020-04-012020-04-30
0001569329ygyi:CommercialCoffeeSegmentMember2020-04-012020-04-30
0001569329ygyi:CommercialHempSegmentMember2020-04-012020-04-30
0001569329ygyi:MortgageDebtMember2020-04-012020-06-30
0001569329srt:ScenarioForecastMember2020-07-012020-07-31
0001569329ygyi:MortgageDebtMembersrt:ScenarioForecastMember2020-07-012020-09-30
0001569329ygyi:CommercialHempSegmentMembersrt:ScenarioForecastMember2020-11-012020-11-30
0001569329ygyi:CommercialCoffeeSegmentMembersrt:ScenarioForecastMember2021-04-012021-04-30
0001569329srt:ScenarioForecastMember2021-06-012021-06-30
0001569329ygyi:OtherNotesRelatedToLoansForCommercialVansMember2020-06-30
0001569329ygyi:OtherNotesRelatedToLoansForCommercialVansMember2019-12-31
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMember2020-06-30
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMembersrt:ScenarioForecastMember2022-01-31
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMemberus-gaap:PrimeRateMember2020-01-012020-06-30
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMember2020-01-012020-06-30
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMember2019-12-31
0001569329ygyi:PipeNotes2019Member2020-06-30
0001569329ygyi:PipeNotes2019Member2019-12-31
0001569329ygyi:PipeNotes2014Member2020-06-30
0001569329ygyi:PipeNotes2014Member2019-12-31
0001569329ygyi:The2019PrivatePlacementDebtOfferingMember2019-07-31
0001569329ygyi:The2019PrivatePlacementDebtOfferingMember2019-07-31
0001569329ygyi:SubscriptionAgreementMember2019-07-31
0001569329ygyi:PipeNotes2019Member2019-07-31
0001569329ygyi:PipeNotes2019ConvertedIntoCommonStockMember2019-07-31
0001569329ygyi:PipeNotes2019Member2020-01-012020-06-30
0001569329ygyi:PipeNotes2019Member2019-01-012019-06-30
0001569329ygyi:PipeNotes2019AmendmentMembersrt:ScenarioForecastMember2021-03-31
0001569329ygyi:PipeNotes2014Member2014-07-012014-09-30
0001569329ygyi:PipeNotes2014Member2014-09-30
0001569329ygyi:Pipe2014DebtConvertedIntoCommonStockMember2014-07-012014-09-30
0001569329ygyi:Pipe2014DebtConvertedIntoCommonStockMember2014-09-30
0001569329ygyi:WarrantsWith2014PrivatePlacementMember2014-09-30
0001569329us-gaap:AssetNotPledgedAsCollateralMembersrt:ChiefExecutiveOfficerMember2020-06-30
0001569329ygyi:PipeNotes2014Member2019-09-30
0001569329ygyi:PipeNotes2014Member2019-01-012019-06-30
0001569329ygyi:WarrantsMember2020-06-30
0001569329ygyi:WarrantsMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2020-06-30
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2020-06-30
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2020-06-30
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2020-06-30
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2020-06-30
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2020-06-30
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2019-12-31
0001569329us-gaap:FairValueInputsLevel1Member2020-06-30
0001569329us-gaap:FairValueInputsLevel2Member2020-06-30
0001569329us-gaap:FairValueInputsLevel3Member2020-06-30
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel1Member2020-06-30
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel2Member2020-06-30
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Member2020-06-30
0001569329us-gaap:FairValueInputsLevel1Member2019-12-31
0001569329us-gaap:FairValueInputsLevel2Member2019-12-31
0001569329us-gaap:FairValueInputsLevel3Member2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel1Member2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel2Member2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Member2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2020-01-012020-06-30
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-06-30
0001569329us-gaap:FairValueInputsLevel3Memberygyi:ContingentLiabilitiesMember2019-12-31
0001569329us-gaap:FairValueInputsLevel3Memberygyi:ContingentLiabilitiesMember2020-01-012020-06-30
0001569329us-gaap:FairValueInputsLevel3Memberygyi:ContingentLiabilitiesMember2020-06-30
0001569329us-gaap:MeasurementInputDiscountRateMember2020-06-30
0001569329us-gaap:MeasurementInputDiscountRateMember2019-12-31
0001569329us-gaap:SeriesCPreferredStockMember2020-06-30
00015693292018-05-31
0001569329ygyi:March2020PrivatePlacementDebtOfferingMember2020-03-31
0001569329ygyi:March2020PrivatePlacementDebtOfferingMember2020-03-012020-03-31
0001569329ygyi:March2020PrivatePlacementDebtOfferingMember2020-03-31
0001569329ygyi:SeniorSecuredPromissoryNoteWithSecuritiesPurchaseAgreementMember2020-03-012020-03-31
0001569329ygyi:SeniorSecuredPromissoryNoteWithSecuritiesPurchaseAgreementMember2020-03-012020-03-31
0001569329srt:ScenarioForecastMemberygyi:SeniorSecuredPromissoryNoteWithSecuritiesPurchaseAgreementMember2021-04-012021-04-30
0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-06-012019-06-30
0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-06-30
0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-02-012019-02-28
0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-02-28
0001569329ygyi:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember2019-02-28
0001569329ygyi:PurchaseAgreementSharesIssuedForConsultingFeesMember2019-02-012019-02-28
0001569329ygyi:PurchaseAgreementSharesIssuedForConsultingFeesMember2019-02-28
0001569329ygyi:PurchaseAgreementsWarrantsForConsultingFeesMember2019-02-28
00015693292019-03-012020-06-30
0001569329ygyi:The2019PrivatePlacementDebtOfferingMember2019-02-012019-07-31
0001569329ygyi:StockIssuedToPlacementAgentMember2019-02-012019-07-31
0001569329srt:ScenarioForecastMemberygyi:StockIssuedToPlacementAgentMember2021-02-012021-03-31
0001569329ygyi:AtthemarketEquityOfferingProgramMember2019-01-31
0001569329ygyi:AtthemarketEquityOfferingProgramMember2019-01-012019-01-31
0001569329ygyi:PrivatePlacement2018Member2018-08-012018-10-31
0001569329ygyi:PrivatePlacement2018Member2018-10-31
0001569329ygyi:StockIssuedForAdvisoryFeesMember2018-08-012018-10-31
0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMember2018-10-31
0001569329ygyi:PrivatePlacement2018Member2019-01-012019-12-31
0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMember2020-06-30
0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMember2019-12-31
0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMemberygyi:ReclassifiedFromDerivativeLiabilityToEquityMember2019-01-01
0001569329ygyi:ConversionOf2014ConvertibleNoteIntoCommonStockMember2018-10-012018-10-31
0001569329ygyi:ConversionOf2014ConvertibleNoteIntoCommonStockMember2018-10-31
0001569329ygyi:WarrantsWith2014ConvertibleNoteMember2018-10-31
0001569329ygyi:WarrantsWith2014ConvertibleNoteMember2020-06-30
0001569329ygyi:WarrantsWith2014ConvertibleNoteMember2019-12-31
0001569329ygyi:StockIssuedToDebtExchangeDealerMember2018-10-012018-10-31
0001569329ygyi:WarrantsToDebtExchangeDealerOneMember2018-10-31
0001569329ygyi:WarrantsToDebtExchangeDealerTwoMember2018-10-31
0001569329ygyi:WarrantsToDebtExchangeDealerMember2020-06-30
0001569329ygyi:WarrantsToDebtExchangeDealerMember2019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2018-03-012018-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2018-03-31
0001569329ygyi:WarrantsWithSeriesBOfferingMember2018-03-012018-03-31
0001569329ygyi:WarrantsWithSeriesBOfferingMember2018-03-31
0001569329ygyi:WarrantsWithSeriesBOfferingMember2020-06-30
0001569329ygyi:WarrantsWithSeriesBOfferingMember2019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2020-03-31
0001569329ygyi:ConversionOfSeriesBPreferredStockIntoCommonStockMember2020-01-012020-03-31
0001569329ygyi:ConversionOfSeriesBPreferredStockIntoCommonStockMember2019-01-012019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2019-01-012019-06-30
0001569329ygyi:WarrantsWithSeriesCOfferingMember2018-01-012018-12-31
0001569329ygyi:WarrantsWithSeriesCOfferingMember2018-12-31
0001569329us-gaap:SeriesCPreferredStockMember2019-12-31
0001569329ygyi:WarrantsWithSeriesCOfferingMember2019-01-012019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-09-012019-12-31
0001569329srt:WeightedAverageMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2019-09-012019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2020-01-012020-01-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2020-01-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-09-012020-06-30
0001569329ygyi:CapitalMarketSolutionsLlcMember2018-07-012018-07-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2020-01-012020-06-30
0001569329ygyi:CapitalMarketSolutionsLlcMember2019-01-012019-01-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2019-01-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2020-01-31
0001569329ygyi:CapitalMarketSolutionsLlcMembersrt:ScenarioForecastMember2021-01-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2019-01-012019-06-30
0001569329ygyi:CorinthianPartnersLlcMember2019-08-012019-08-31
0001569329ygyi:GreentreeFinancialGroupIncMember2018-03-012018-03-31
0001569329ygyi:GreentreeFinancialGroupIncMember2019-01-012019-06-30
0001569329ygyi:IbankersMember2019-04-012019-04-30
0001569329ygyi:IbankersMember2019-01-012019-06-30
0001569329ygyi:IgnitionMember2018-04-012018-04-30
0001569329ygyi:IgnitionMember2019-01-012019-06-30
0001569329ygyi:IgnitionMember2019-03-012019-03-31
0001569329ygyi:IgnitionMember2019-03-31
0001569329ygyi:IvanGandrudChevroletIncMember2020-03-012020-03-31
0001569329ygyi:IvanGandrudChevroletIncMember2020-03-31
0001569329ygyi:IvanGandrudChevroletIncMember2020-01-012020-06-30
0001569329ygyi:IvanGandrudChevroletIncMemberygyi:MrDanielManglessMember2020-06-30
0001569329ygyi:BenchmarkCompanyMember2019-08-012019-08-31
0001569329srt:MinimumMember2020-06-30
0001569329srt:MaximumMember2020-06-30
0001569329us-gaap:CostOfSalesMember2020-04-012020-06-30
0001569329us-gaap:CostOfSalesMember2019-04-012019-06-30
0001569329us-gaap:CostOfSalesMember2020-01-012020-06-30
0001569329us-gaap:CostOfSalesMember2019-01-012019-06-30
0001569329us-gaap:SellingAndMarketingExpenseMember2020-04-012020-06-30
0001569329us-gaap:SellingAndMarketingExpenseMember2019-04-012019-06-30
0001569329us-gaap:SellingAndMarketingExpenseMember2020-01-012020-06-30
0001569329us-gaap:SellingAndMarketingExpenseMember2019-01-012019-06-30
0001569329us-gaap:GeneralAndAdministrativeExpenseMember2020-04-012020-06-30
0001569329us-gaap:GeneralAndAdministrativeExpenseMember2019-04-012019-06-30
0001569329us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-06-30
0001569329us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-06-30
00015693292019-01-012019-12-31
0001569329us-gaap:EmployeeStockOptionMember2020-01-012020-06-30
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:ConsultantsMember2019-08-012019-08-31
00015693292019-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMember2017-08-012017-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2017-08-012017-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2017-08-012017-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2017-08-012017-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberygyi:SharebasedPaymentArrangementTrancheFourMember2017-08-012017-08-31
00015693292017-08-31 00015693292019-01-01
0001569329us-gaap:RestrictedStockUnitsRSUMember2019-12-31
0001569329us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-30
0001569329us-gaap:RestrictedStockUnitsRSUMember2020-06-30
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMember2020-06-30
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMember2020-01-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2020-04-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2020-04-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2020-01-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2020-01-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2019-04-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2019-04-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2019-01-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2019-01-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-04-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialCoffeeSegmentMember2020-04-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-04-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:FourVendorsMemberygyi:CommercialCoffeeSegmentMember2019-04-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-04-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialHempSegmentMember2020-04-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-01-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialHempSegmentMember2020-01-012020-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-04-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:ThreeVendorsMemberygyi:CommercialHempSegmentMember2019-04-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-01-012019-06-30
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialHempSegmentMember2019-01-012019-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-04-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:ThreeCustomersMemberygyi:CommercialCoffeeSegmentMember2020-04-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:TwoCustomersMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-04-012019-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:TwoCustomersMemberygyi:CommercialCoffeeSegmentMember2019-04-012019-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:OneCustomerMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-04-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:OneCustomerMemberygyi:CommercialHempSegmentMember2020-04-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-01-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:OneCustomerMemberygyi:CommercialHempSegmentMember2020-01-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-04-012019-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:ThreeCustomersMemberygyi:CommercialHempSegmentMember2019-04-012019-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-01-012019-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:ThreeCustomersMemberygyi:CommercialHempSegmentMember2019-01-012019-06-30
0001569329ygyi:CommercialHempSegmentMember2019-06-30
0001569329us-gaap:NonUsMember2020-06-30
0001569329us-gaap:NonUsMember2019-12-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2020-04-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2019-04-012019-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2020-01-012020-06-30
0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2019-01-012019-06-30
0001569329country:US2020-04-012020-06-30
0001569329country:US2019-04-012019-06-30
0001569329country:US2020-01-012020-06-30
0001569329country:US2019-01-012019-06-30
0001569329us-gaap:NonUsMember2020-04-012020-06-30
0001569329us-gaap:NonUsMember2019-04-012019-06-30
0001569329us-gaap:NonUsMember2020-01-012020-06-30
0001569329us-gaap:NonUsMember2019-01-012019-06-30
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMembersrt:ScenarioForecastMember2022-06-17
0001569329ygyi:MrDanielManglessMembersrt:ScenarioForecastMember2021-02-28
0001569329ygyi:AllClaimsRelatedToLawsuitFiledByMrManglessMembersrt:ScenarioForecastMember2021-04-012021-04-30
0001569329srt:ScenarioForecastMemberygyi:SettlementSharesMember2021-04-012021-04-30
0001569329ygyi:CbdOilExtractionEquipmentWithVfiMembersrt:ScenarioForecastMember2020-08-31
0001569329ygyi:CbdOilExtractionEquipmentWithVfiMembersrt:ScenarioForecastMember2020-08-012020-08-31
0001569329ygyi:CommercialHempSegmentMembersrt:ScenarioForecastMember2020-04-012020-07-31
0001569329ygyi:MortgageDebtMembersrt:ScenarioForecastMember2020-01-012020-09-30
0001569329srt:ScenarioForecastMember2021-02-28
0001569329ygyi:DirectSellingSegmentMembersrt:ScenarioForecastMember2021-06-012021-06-30
0001569329ygyi:CommercialCoffeeSegmentMembersrt:ScenarioForecastMember2021-06-012021-06-30
0001569329ygyi:PipeNotes2019Membersrt:ScenarioForecastMember2021-02-28
0001569329srt:ScenarioForecastMemberygyi:StockInConnectionWith2019PipeNotesMember2021-02-012021-02-28
0001569329ygyi:PipeNotes2019Membersrt:ScenarioForecastMember2021-03-31
0001569329srt:ScenarioForecastMemberygyi:StockInConnectionWith2019PipeNotesMember2021-03-012021-03-31
0001569329ygyi:PromissoryNotes2019Membersrt:ScenarioForecastMember2021-02-28
0001569329srt:ScenarioForecastMemberygyi:SharesInConnectionWithPromissoryNotes2019Member2021-02-012021-02-28
0001569329ygyi:WarrantsInConnectionWithPromissoryNotes2019Membersrt:ScenarioForecastMember2021-02-28
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2022-05-31
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2022-05-012022-05-31
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2021-09-30
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2021-09-012021-09-30
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:LendingAgreementMembersrt:MinimumMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:LendingAgreementMembersrt:MaximumMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:LendingAgreementMember2020-05-31
0001569329ygyi:CLRMemberygyi:HhMembersrt:ScenarioForecastMember2021-03-31
0001569329ygyi:TradeAccountsReceivablesMemberygyi:CLRMemberygyi:HhMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:CLRMemberygyi:HhMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:GrovelandPropertyMembersrt:ScenarioForecastMember2021-05-012021-05-31
0001569329ygyi:MascotteFacilityMembersrt:ScenarioForecastMember2021-10-012021-10-31
0001569329ygyi:ClermontPropertyMembersrt:ScenarioForecastMember2022-02-012022-02-28
0001569329us-gaap:RestrictedStockUnitsRSUMembersrt:ScenarioForecastMember2020-08-012020-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMembersrt:ScenarioForecastMember2021-08-012021-08-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2020-07-012020-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2021-01-012021-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2022-01-012022-06-15
0001569329ygyi:BeneyouMember2020-01-012020-06-30
0001569329us-gaap:ConvertibleNotesPayableMember2020-01-012020-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
☒ |
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the quarterly period ended June 30, 2020
|
☐ |
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the transition period from ______ to ______
Commission file number: 001-38116
YOUNGEVITY
INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
|
|
90-0890517
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
2400 Boswell Road,
Chula Vista, CA
|
|
91914
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(619)
934-3980
Registrant’s Telephone Number, Including Area Code
Not
applicable
Former Name, Former Address and Former Fiscal Year, if Changed
Since Last Report
Securities registered pursuant to Section 12(b) of the Act:
None
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
N/A
|
N/A
|
N/A
|
Indicate by check mark whether the registrant (1) filed all reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90
days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this
chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files). Yes
☐ No ☒
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer
|
☐ |
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
|
|
Emerging growth company
|
☐ |
If an emerging growth company indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
As of June 17, 2022, the issuer had 34,044,419 shares of
its Common Stock, par value $0.001 per share, issued and
outstanding.
YOUNGEVITY INTERNATIONAL,
INC.
TABLE OF CONTENTS
PART
I. FINANCIAL INFORMATION
Item 1. Financial Statements
Youngevity International, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
|
|
June 30,
2020
|
|
|
December 31,
2019
|
|
ASSETS
|
|
(Unaudited)
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
1,087 |
|
|
$ |
4,463 |
|
Accounts receivable, trade
|
|
|
2,452 |
|
|
|
2,902 |
|
Income tax receivable
|
|
|
81 |
|
|
|
81 |
|
Inventory
|
|
|
22,982 |
|
|
|
22,706 |
|
Prepaid expenses and other current assets
|
|
|
5,947 |
|
|
|
3,982 |
|
Total current assets
|
|
|
32,549 |
|
|
|
34,134 |
|
Property and equipment, net
|
|
|
24,351 |
|
|
|
23,316 |
|
Operating lease right-of-use assets
|
|
|
7,325 |
|
|
|
8,386 |
|
Deferred tax assets
|
|
|
75 |
|
|
|
75 |
|
Intangible assets, net
|
|
|
14,326 |
|
|
|
15,566 |
|
Goodwill
|
|
|
6,992 |
|
|
|
6,992 |
|
Other assets
|
|
|
1,274 |
|
|
|
1,222 |
|
Total assets
|
|
$ |
86,892 |
|
|
$ |
89,691 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$ |
9,237 |
|
|
$ |
9,069 |
|
Accrued distributor compensation
|
|
|
3,725 |
|
|
|
3,164 |
|
Accrued expenses
|
|
|
6,385 |
|
|
|
5,108 |
|
Deferred revenues
|
|
|
5,447 |
|
|
|
1,943 |
|
Line of credit
|
|
|
1,499 |
|
|
|
2,011 |
|
Other current liabilities
|
|
|
2,593 |
|
|
|
2,664 |
|
Operating lease liabilities
|
|
|
1,584 |
|
|
|
1,740 |
|
Finance lease liabilities, current portion
|
|
|
856 |
|
|
|
736 |
|
Notes payable, net of debt discounts, current portion (Note 3)
|
|
|
4,800 |
|
|
|
4,085 |
|
Notes payable, net of debt discounts, current portion
|
|
|
2,064 |
|
|
|
191 |
|
Convertible notes payable, net of debt discounts, current
portion
|
|
|
2,868 |
|
|
|
25 |
|
Other current loans |
|
|
3,773 |
|
|
|
- |
|
Warrant derivative liability
|
|
|
101 |
|
|
|
1,542 |
|
Contingent acquisition debt, current portion
|
|
|
1,166 |
|
|
|
1,263 |
|
Total current liabilities
|
|
|
46,098 |
|
|
|
33,541 |
|
Operating lease liabilities, net of current portion
|
|
|
5,928 |
|
|
|
6,646 |
|
Finance lease liabilities, net of current portion
|
|
|
314 |
|
|
|
408 |
|
Notes payable, net of debt discounts, net of current portion (Note
3)
|
|
|
671 |
|
|
|
- |
|
Notes payable, net of debt discounts, net of current portion
|
|
|
4,922 |
|
|
|
6,790 |
|
Convertible notes payable, net of debt discounts, net of current
portion
|
|
|
- |
|
|
|
2,675 |
|
Contingent acquisition debt, net of current portion
|
|
|
6,264 |
|
|
|
7,348 |
|
Other long-term liabilities
|
|
|
427 |
|
|
|
2,115 |
|
Total liabilities
|
|
|
64,624 |
|
|
|
59,523 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 11)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ Equity
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001
par value: 5,000,000 shares
authorized
|
|
|
|
|
|
|
|
|
Series A – 8% convertible preferred
stock; 161,135
shares issued and outstanding at June 30, 2020 and December 31,
2019
|
|
|
– |
|
|
|
– |
|
Series B – 5% convertible preferred
stock; zero and 129,332 shares issued and
outstanding at June 30, 2020 and December 31, 2019,
respectively
|
|
|
– |
|
|
|
– |
|
Series D – 9.75% cumulative
redeemable perpetual preferred stock; 590,273 and 578,898 shares issued and
outstanding at June 30, 2020 and December 31, 2019, respectively;
$14,877 liquidation preference at June 30, 2020
|
|
|
– |
|
|
|
– |
|
Common stock, $0.001 par value:
50,000,000 shares
authorized; 32,216,599 and
30,274,601 shares issued
and outstanding at June 30, 2020 and December 31, 2019,
respectively
|
|
|
32 |
|
|
|
30 |
|
Additional paid-in capital
|
|
|
268,473 |
|
|
|
265,825 |
|
Accumulated deficit
|
|
|
(246,082 |
) |
|
|
(235,751 |
) |
Accumulated other comprehensive income (loss)
|
|
|
(155 |
) |
|
|
64 |
|
Total stockholders’ equity
|
|
|
22,268 |
|
|
|
30,168 |
|
Total Liabilities and Stockholders’ Equity
|
|
$ |
86,892 |
|
|
$ |
89,691 |
|
See accompanying notes to condensed consolidated financial
statements.
Youngevity International, Inc. and
Subsidiaries
Unaudited Condensed Consolidated Statements of
Operations
(In thousands, except share and per share amounts)
|
|
Three Months Ended
June 30,
|
|
|
Six Months Ended
June 30,
|
|
|
|
2020
|
|
|
2019
|
|
|
2020
|
|
|
2019
|
|
Revenues
|
|
$ |
32,992 |
|
|
$ |
38,217 |
|
|
$ |
68,523 |
|
|
$ |
79,409 |
|
Cost of revenues
|
|
|
12,946 |
|
|
|
12,537 |
|
|
|
28,690 |
|
|
|
26,880 |
|
Gross profit
|
|
|
20,046 |
|
|
|
25,680 |
|
|
|
39,833 |
|
|
|
52,529 |
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributor compensation
|
|
|
12,731 |
|
|
|
14,497 |
|
|
|
26,782 |
|
|
|
29,387 |
|
Sales and marketing
|
|
|
2,872 |
|
|
|
2,786 |
|
|
|
6,345 |
|
|
|
6,805 |
|
General and administrative
|
|
|
8,295 |
|
|
|
8,251 |
|
|
|
17,235 |
|
|
|
28,132 |
|
Total operating expenses
|
|
|
23,898 |
|
|
|
25,534 |
|
|
|
50,362 |
|
|
|
64,324 |
|
Operating income (loss)
|
|
|
(3,852 |
)
|
|
|
146 |
|
|
|
(10,529 |
)
|
|
|
(11,795 |
)
|
Other income (expenses), net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
(639 |
)
|
|
|
(1,062 |
)
|
|
|
(1,259 |
)
|
|
|
(2,569 |
)
|
Change in fair value of warrant derivative liability
|
|
|
(48 |
)
|
|
|
401 |
|
|
|
1,441 |
|
|
|
1,887 |
|
Total other income (expenses), net
|
|
|
(687 |
)
|
|
|
(661 |
)
|
|
|
182 |
|
|
|
(682 |
)
|
Loss before income taxes
|
|
|
(4,539 |
)
|
|
|
(515 |
)
|
|
|
(10,347 |
)
|
|
|
(12,477 |
)
|
Income tax provision(benefit)
|
|
|
1 |
|
|
|
(226 |
)
|
|
|
(16 |
)
|
|
|
72 |
|
Net loss
|
|
|
(4,540 |
)
|
|
|
(289 |
)
|
|
|
(10,331 |
)
|
|
|
(12,549 |
)
|
Preferred stock dividends
|
|
|
(363 |
)
|
|
|
(28 |
)
|
|
|
(742 |
)
|
|
|
(42 |
)
|
Net loss attributable to common stockholders
|
|
$ |
(4,903 |
)
|
|
$ |
(317 |
)
|
|
$ |
(11,073 |
)
|
|
$ |
(12,591 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic
|
|
$ |
(0.15 |
)
|
|
$ |
(0.01 |
)
|
|
$ |
(0.36 |
)
|
|
$ |
(0.44 |
)
|
Net loss per share, diluted (Note 1)
|
|
$ |
(0.15 |
)
|
|
$ |
(0.02 |
)
|
|
$ |
(0.36 |
)
|
|
$ |
(0.49 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding, basic
|
|
|
31,882,762 |
|
|
|
29,133,150 |
|
|
|
31,098,874 |
|
|
|
28,359,660 |
|
Weighted average shares outstanding, diluted
|
|
|
31,882,762 |
|
|
|
29,357,347 |
|
|
|
31,098,874 |
|
|
|
28,700,295 |
|
See accompanying notes to condensed consolidated financial
statements.
Youngevity International, Inc. and
Subsidiaries
Unaudited Condensed Consolidated Statements of
Comprehensive Loss
(In thousands)
|
|
Three Months Ended
June 30,
|
|
|
Six Months Ended
June 30,
|
|
|
|
2020
|
|
|
2019
|
|
|
2020
|
|
|
2019
|
|
Net loss
|
|
$ |
(4,540 |
)
|
|
$ |
(289 |
)
|
|
$ |
(10,331 |
)
|
|
$ |
(12,549 |
)
|
Foreign currency translation
|
|
|
(242 |
)
|
|
|
(62 |
)
|
|
|
(219 |
)
|
|
|
40 |
|
Total other comprehensive income (loss)
|
|
|
(242 |
)
|
|
|
(62 |
)
|
|
|
(219 |
)
|
|
|
40 |
|
Comprehensive loss
|
|
$ |
(4,782 |
)
|
|
$ |
(351 |
)
|
|
$ |
(10,550 |
)
|
|
$ |
(12,509 |
)
|
See accompanying notes to condensed consolidated financial
statements.
Youngevity International, Inc. and
Subsidiaries
Unaudited Condensed Consolidated Statements of Stockholders'
Equity
(In thousands, except shares)
|
|
Three Months Ended June 30, 2020 |
|
|
|
Preferred Stock
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
Accumulated Other Comprehensive
|
|
|
|
|
|
|
|
|
|
|
|
Series A
|
|
|
Series B
|
|
|
Series D
|
|
|
Common Stock
|
|
|
Paid-in
|
|
|
Income
|
|
|
Accumulated
|
|
|
Stockholders'
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
(Loss)
|
|
|
Deficit
|
|
|
Equity
|
|
Balance at March 31, 2020
|
|
|
161,135 |
|
|
$ |
– |
|
|
|
– |
|
|
$ |
– |
|
|
|
590,273 |
|
|
$ |
– |
|
|
|
30,712,432 |
|
|
$ |
31 |
|
|
$ |
265,867 |
|
|
$ |
87 |
|
|
$ |
(241,542 |
)
|
|
$ |
24,443 |
|
Net loss
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(4,540 |
)
|
|
|
(4,540 |
)
|
Foreign currency translation adjustment
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(242 |
)
|
|
|
– |
|
|
|
(242 |
)
|
Issuance of common stock for vesting of RSU
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
4,167 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
Fair value of common stock issued related to Nica Hemp Project
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
1,500,000 |
|
|
|
1 |
|
|
|
2,489 |
|
|
|
– |
|
|
|
– |
|
|
|
2,490 |
|
Fair value of common stock issued related to advance for working
capital (recorded in prepaid expenses and other current assets)
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
88 |
|
|
|
– |
|
|
|
– |
|
|
|
88 |
|
Dividends on preferred stock
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(363 |
)
|
|
|
– |
|
|
|
– |
|
|
|
(363 |
)
|
Equity-based compensation for services
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
127 |
|
|
|
– |
|
|
|
– |
|
|
|
127 |
|
Stock-based compensation
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
265 |
|
|
|
– |
|
|
|
– |
|
|
|
265 |
|
Balance at June 30, 2020
|
|
|
161,135 |
|
|
$ |
– |
|
|
|
– |
|
|
$ |
– |
|
|
|
590,273 |
|
|
$ |
– |
|
|
|
32,216,599 |
|
|
$ |
32 |
|
|
$ |
268,473 |
|
|
$ |
(155 |
) |
|
$ |
(246,082 |
)
|
|
$ |
22,268 |
|
|
|
Six Months Ended June 30, 2020 |
|
|
|
Preferred Stock
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
Accumulated Other Comprehensive
|
|
|
|
|
|
|
|
|
|
|
|
Series A
|
|
|
Series B
|
|
|
Series D
|
|
|
Common Stock
|
|
|
Paid-in
|
|
|
Income
|
|
|
Accumulated
|
|
|
Stockholders'
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
(Loss)
|
|
|
Deficit
|
|
|
Equity
|
|
Balance at December 31, 2019
|
|
|
161,135 |
|
|
$ |
– |
|
|
|
129,332 |
|
|
$ |
– |
|
|
|
578,898 |
|
|
$ |
– |
|
|
|
30,274,601 |
|
|
$ |
30 |
|
|
$ |
265,825 |
|
|
$ |
64 |
|
|
$ |
(235,751 |
)
|
|
$ |
30,168 |
|
Net loss
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
- |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(10,331 |
)
|
|
|
(10,331 |
)
|
Foreign currency translation adjustment
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(219 |
)
|
|
|
– |
|
|
|
(219 |
)
|
Issuance of common stock for conversion of Series B preferred
stock
|
|
|
– |
|
|
|
– |
|
|
|
(129,332 |
)
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
258,664 |
|
|
|
1 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
1 |
|
Issuance of common stock for vesting of RSU
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
8,334 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
- |
|
Issuance of common stock for debt financing, net of issuance
costs
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
50,000 |
|
|
|
– |
|
|
|
65 |
|
|
|
– |
|
|
|
– |
|
|
|
65 |
|
Fair value of common stock issued related to Nica Hemp Project
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
1,500,000 |
|
|
|
1 |
|
|
|
2,489 |
|
|
|
– |
|
|
|
– |
|
|
|
2,490 |
|
Issuance of Series D preferred stock through underwritten
registered public offering, net
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
11,375 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
233 |
|
|
|
– |
|
|
|
– |
|
|
|
233 |
|
Fair value of common stock issued related to advance for working
capital (recorded in prepaid expenses and other current assets)
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(223 |
)
|
|
|
– |
|
|
|
– |
|
|
|
(223 |
)
|
Dividends on preferred stock
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(742 |
)
|
|
|
– |
|
|
|
– |
|
|
|
(742 |
)
|
Equity-based compensation for services
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
125,000 |
|
|
|
– |
|
|
|
301 |
|
|
|
– |
|
|
|
– |
|
|
|
301 |
|
Stock-based compensation
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
525 |
|
|
|
– |
|
|
|
– |
|
|
|
525 |
|
Balance at June 30, 2020
|
|
|
161,135 |
|
|
$ |
– |
|
|
|
– |
|
|
$ |
– |
|
|
|
590,273 |
|
|
$ |
– |
|
|
|
32,216,599 |
|
|
$ |
32 |
|
|
$ |
268,473 |
|
|
$ |
(155 |
)
|
|
$ |
(246,082 |
)
|
|
$ |
22,268 |
|
See accompanying notes to condensed consolidated financial
statements.
Youngevity International, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Stockholders'
Equity
(In thousands, except shares)
|
|
Three Months Ended June 30, 2019
|
|
|
|
Series A
Preferred Stock
|
|
|
Series B
Preferred Stock
|
|
|
Common Stock
|
|
|
Additional
Paid-in
|
|
|
Accumulated
Other
Comprehensive Income
|
|
|
Accumulated
|
|
|
Total Stockholders'
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
(Loss)
|
|
|
Deficit
|
|
|
Equity
|
|
Balance at March 31, 2019
|
|
|
161,135 |
|
|
$ |
- |
|
|
|
129,437 |
|
|
$ |
- |
|
|
|
28,890,671 |
|
|
$ |
29 |
|
|
$ |
244,906 |
|
|
$ |
57 |
|
|
$ |
(196,023 |
)
|
|
$ |
48,969 |
|
Net loss
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(289 |
)
|
|
|
(289 |
)
|
Foreign currency translation adjustment
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(62 |
)
|
|
|
- |
|
|
|
(62 |
)
|
Issuance of common stock from exercise of stock options and
warrants, net
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
64,524 |
|
|
|
- |
|
|
|
293 |
|
|
|
- |
|
|
|
- |
|
|
|
293 |
|
Issuance of common stock for services
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
100,000 |
|
|
|
- |
|
|
|
571 |
|
|
|
- |
|
|
|
- |
|
|
|
571 |
|
Issuance of common stock in private offering, net of issuance
costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
250,000 |
|
|
|
- |
|
|
|
1,375 |
|
|
|
- |
|
|
|
- |
|
|
|
1,375 |
|
Issuance of common stock for convertible note financing, net of
issuance costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
11,250 |
|
|
|
- |
|
|
|
135 |
|
|
|
- |
|
|
|
- |
|
|
|
135 |
|
Warrant issued upon vesting for services
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
270 |
|
|
|
- |
|
|
|
- |
|
|
|
270 |
|
Dividends on preferred stock
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(28 |
)
|
|
|
- |
|
|
|
- |
|
|
|
(28 |
)
|
Stock based compensation expense
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
413 |
|
|
|
- |
|
|
|
- |
|
|
|
413 |
|
Balance at June 30, 2019
|
|
|
161,135 |
|
|
$ |
- |
|
|
|
129,437 |
|
|
$ |
- |
|
|
|
29,316,445 |
|
|
$ |
29 |
|
|
$ |
247,935 |
|
|
$ |
(5 |
)
|
|
$ |
(196,312 |
)
|
|
$ |
51,647 |
|
|
|
Six Months Ended June 30, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A
Preferred Stock
|
|
|
Series B
Preferred Stock
|
|
|
Common Stock
|
|
|
Additional
Paid-in
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Accumulated
|
|
|
Total Stockholders'
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Loss
|
|
|
Deficit
|
|
|
Equity
|
|
Balance at December 31, 2018
|
|
|
161,135 |
|
|
$ |
- |
|
|
|
129,437 |
|
|
$ |
- |
|
|
|
25,760,708 |
|
|
$ |
26 |
|
|
$ |
206,757 |
|
|
$ |
(45 |
)
|
|
$ |
(183,763 |
)
|
|
$ |
22,975 |
|
Net loss
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(12,549 |
)
|
|
|
(12,549 |
)
|
Foreign currency translation adjustment
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
40 |
|
|
|
- |
|
|
|
40 |
|
Issuance of common stock from at-the-market offering and exercise
of stock options and warrants, net
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
374,160 |
|
|
|
1 |
|
|
|
1,747 |
|
|
|
- |
|
|
|
- |
|
|
|
1,748 |
|
Issuance of common stock for services
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
175,000 |
|
|
|
- |
|
|
|
988 |
|
|
|
- |
|
|
|
- |
|
|
|
988 |
|
Issuance of common stock in private offering, net of issuance
costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
505,000 |
|
|
|
- |
|
|
|
3,125 |
|
|
|
- |
|
|
|
- |
|
|
|
3,125 |
|
Issuance of common stock for acquisition of Khrysos
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,794,972 |
|
|
|
1 |
|
|
|
13,999 |
|
|
|
- |
|
|
|
- |
|
|
|
14,000 |
|
Issuance of common stock for debt financing, net of issuance
costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
40,000 |
|
|
|
- |
|
|
|
350 |
|
|
|
- |
|
|
|
- |
|
|
|
350 |
|
Issuance of common stock for true-up shares
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
44,599 |
|
|
|
- |
|
|
|
281 |
|
|
|
- |
|
|
|
- |
|
|
|
281 |
|
Issuance of common stock for convertible note financing, net of
issuance costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
72,250 |
|
|
|
- |
|
|
|
428 |
|
|
|
- |
|
|
|
- |
|
|
|
428 |
|
Issuance of common stock related to purchase of land - H&H
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
153,846 |
|
|
|
- |
|
|
|
1,200 |
|
|
|
- |
|
|
|
- |
|
|
|
1,200 |
|
Issuance of common stock related to purchase of trademark -
H&H
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
100,000 |
|
|
|
- |
|
|
|
750 |
|
|
|
- |
|
|
|
- |
|
|
|
750 |
|
Issuance of common stock related to advance for working capital
(note receivable) net of settlement of debt
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
295,910 |
|
|
|
1 |
|
|
|
2,308 |
|
|
|
- |
|
|
|
- |
|
|
|
2,309 |
|
Release of warrant liability upon exercise of warrants
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
866 |
|
|
|
- |
|
|
|
- |
|
|
|
866 |
|
Release of warrant liability upon reclassification of liability to
equity
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,494 |
|
|
|
- |
|
|
|
- |
|
|
|
1,494 |
|
Warrant issued upon vesting for services
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,926 |
|
|
|
- |
|
|
|
- |
|
|
|
1,926 |
|
Dividends on preferred stock
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(42 |
)
|
|
|
- |
|
|
|
- |
|
|
|
(42 |
)
|
Stock based compensation expense
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
11,757 |
|
|
|
- |
|
|
|
- |
|
|
|
11,757 |
|
Balance at June 30, 2019
|
|
|
161,135 |
|
|
$ |
- |
|
|
|
129,437 |
|
|
$ |
- |
|
|
|
29,316,445 |
|
|
$ |
29 |
|
|
$ |
247,935 |
|
|
$ |
(5 |
)
|
|
$ |
(196,312 |
)
|
|
$ |
51,647 |
|
See accompanying notes to condensed consolidated financial
statements.
Youngevity International, Inc. and
Subsidiaries
Unaudited Condensed Consolidated Statements of
Cash Flows
(In thousands)
|
|
Six Months Ended
June 30,
|
|
|
|
2020
|
|
|
2019 |
|
Cash Flows from Operating Activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(10,331 |
)
|
|
$ |
(12,549 |
)
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
2,573 |
|
|
|
2,333 |
|
Stock-based compensation expense
|
|
|
525 |
|
|
|
11,757 |
|
Equity-based compensation for services
|
|
|
911 |
|
|
|
2,541 |
|
Amortization of debt discounts and issuance costs
|
|
|
707 |
|
|
|
534 |
|
Gain on debt extinguishment
|
|
|
(24 |
)
|
|
|
- |
|
Change in fair value of warrant derivative liability
|
|
|
(1,441 |
)
|
|
|
(1,887 |
)
|
Change in fair value of contingent acquisition debt
|
|
|
(1,034 |
)
|
|
|
(433 |
)
|
Change in allowance for doubtful accounts
|
|
|
(30 |
)
|
|
|
- |
|
Change in allowance for other receivable (Note 3)
|
|
|
(224 |
)
|
|
|
- |
|
Change in allowance for notes receivable (Note 3)
|
|
|
224 |
|
|
|
- |
|
Loss on disposal of property and equipment
|
|
|
13 |
|
|
|
- |
|
Changes in inventory reserve
|
|
|
(323 |
)
|
|
|
159 |
|
Non-cash operating lease expense
|
|
|
1,061 |
|
|
|
- |
|
Stock issuance for true-up shares
|
|
|
- |
|
|
|
281 |
|
Deferred taxes
|
|
|
- |
|
|
|
73 |
|
Changes in operating assets and liabilities, net of effect from
business combinations:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
481 |
|
|
|
(5,965 |
)
|
Inventory
|
|
|
47 |
|
|
|
(1,916 |
)
|
Prepaid expenses and other current assets
|
|
|
(85 |
)
|
|
|
(844 |
)
|
Other assets
|
|
|
(278 |
)
|
|
|
- |
|
Accounts payable
|
|
|
167 |
|
|
|
(1,065 |
)
|
Accrued distributor compensation
|
|
|
561 |
|
|
|
451 |
|
Deferred revenues
|
|
|
3,504 |
|
|
|
(52 |
)
|
Accrued expenses and other liabilities
|
|
|
1,216 |
|
|
|
1,358 |
|
Operating lease liabilities
|
|
|
(874 |
)
|
|
|
- |
|
Income taxes receivable
|
|
|
- |
|
|
|
(157 |
)
|
Other long-term liabilities
|
|
|
(1,719 |
)
|
|
|
- |
|
Net Cash Used in Operating Activities
|
|
|
(4,373 |
)
|
|
|
(5,381 |
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities:
|
|
|
|
|
|
|
|
|
Acquisitions, net of cash acquired
|
|
|
- |
|
|
|
(425 |
)
|
Purchases of property and equipment
|
|
|
(1,954 |
)
|
|
|
(3,269 |
)
|
Net Cash Used in Investing Activities
|
|
|
(1,954 |
)
|
|
|
(3,694 |
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities:
|
|
|
|
|
|
|
|
|
Proceeds from issuance of promissory notes, net of offering
costs
|
|
|
1,000 |
|
|
|
5,125 |
|
Proceeds from private placement of common stock, net of offering
costs
|
|
|
- |
|
|
|
2,684 |
|
Proceeds from at-the-market-offering and exercise of stock options
and warrants, net
|
|
|
- |
|
|
|
1,748 |
|
Proceeds from the issuance of preferred stock – series D
|
|
|
233 |
|
|
|
- |
|
Proceeds from other current loans
|
|
|
3,773 |
|
|
|
- |
|
Payments from line of credit, net
|
|
|
(512 |
)
|
|
|
(254 |
)
|
Payments of notes payable
|
|
|
(58 |
)
|
|
|
(68 |
)
|
Payments of contingent acquisition debt
|
|
|
(147 |
)
|
|
|
(235 |
)
|
Payments of finance leases
|
|
|
(370 |
)
|
|
|
(734 |
)
|
Payments of dividends
|
|
|
(749 |
)
|
|
|
(22 |
)
|
Net Cash Provided by Financing Activities
|
|
|
3,170 |
|
|
|
8,244 |
|
Foreign Currency Effect on Cash
|
|
|
(219 |
)
|
|
|
40 |
|
Net decrease in cash and cash equivalents
|
|
|
(3,376 |
)
|
|
|
(791 |
)
|
Cash and Cash Equivalents, Beginning of Period
|
|
|
4,463 |
|
|
|
2,879 |
|
Cash and Cash Equivalents, End of Period
|
|
$ |
1,087 |
|
|
$ |
2,088 |
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosures of Cash Flow Information
|
|
|
|
|
|
|
|
|
Cash paid during the period for:
|
|
|
|
|
|
|
|
|
Interest
|
|
$ |
589 |
|
|
$ |
1,858 |
|
Income taxes
|
|
$ |
- |
|
|
$ |
148 |
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosures of Noncash Investing and Financing
Activities
|
|
|
|
|
|
|
|
|
Purchases of property and equipment funded by finance leases
|
|
$ |
427 |
|
|
$ |
42 |
|
Purchases of property and equipment funded by mortgage
agreements
|
|
$ |
- |
|
|
$ |
450 |
|
Fair value of stock issued for Nica Hemp Project (Note 3)
|
|
$ |
2,490 |
|
|
$ |
- |
|
Issuance of common stock for promissory note financing (Note
10)
|
|
$ |
65 |
|
|
$ |
988 |
|
Decrease in fair value of common stock issued for in relation to
advance for working capital (Note 3)
|
|
$ |
224 |
|
|
$ |
- |
|
Fair value of stock issued for property and equipment (land)
|
|
$ |
- |
|
|
$ |
1,200 |
|
Fair value of stock issued for purchase of intangibles
(tradename)
|
|
$ |
- |
|
|
$ |
750 |
|
Fair value of stock issued for note receivable, net of debt
settlement
|
|
$ |
- |
|
|
$ |
2,309 |
|
Fair value of stock issued in connection with the acquisition of
Khrysos Global, Inc. (Note 2)
|
|
$ |
- |
|
|
$ |
14,000 |
|
Dividends declared but not paid at the end of period (Note 10)
|
|
$ |
120 |
|
|
$ |
25 |
|
See accompanying notes to condensed consolidated financial
statements.
Youngevity International, Inc. and
Subsidiaries
Notes to Unaudited Condensed Consolidated Financial
Statements
Note 1. Description
of Business and Basis of Presentation
Description of Business
Youngevity International, Inc. (the “Company”) operates in three
segments: (i) the direct selling segment where products are offered
through a global distribution network of preferred customers and
distributors, (ii) the commercial coffee segment where products are
sold directly to businesses and (iii) the commercial hemp segment
where the Company manufactures proprietary systems to provide
end-to-end extraction and processing of hemp feed stock into hemp
oil and hemp extracts, oil extraction services, and contract
manufacturing services.
Information on the operations of the Company’s three segments is as follows:
|
●
|
The direct selling segment is operated through the Company’s
three domestic subsidiaries, AL
Global Corporation, 2400 Boswell
LLC, and Youngevity Global LLC, and twelve foreign subsidiaries:
|
|
●
|
Youngevity Australia Pty. Ltd.,
|
|
●
|
Youngevity Mexico S.A. de CV,
|
|
●
|
Youngevity Russia, LLC,
|
|
●
|
Youngevity Israel, Ltd.,
|
|
●
|
Youngevity Europe SIA (Latvia),
|
|
●
|
Youngevity Colombia S.A.S,
|
|
●
|
Youngevity International Singapore Pte. Ltd.,
|
|
●
|
Youngevity Global LLC, Taiwan Branch,
|
|
●
|
Youngevity Global LLC, Philippine Branch, and
|
|
●
|
Youngevity International (Hong Kong).
|
The Company also operate in Indonesia, Malaysia, and Japan through
its sales force of independent distributors.
|
●
|
The commercial coffee business is operated through the Company’s
wholly-owned subsidiary, CLR Roasters LLC (“CLR”) and its
wholly-owned subsidiary, Siles Plantation Family Group S.A.
(“Siles”).
|
|
●
|
The commercial hemp business is operated through the Company’s
wholly-owned subsidiary, Khrysos Industries, Inc., a Delaware
corporation (“KII”). KII acquired the assets of Khrysos Global
Inc., a Florida corporation (“Khrysos Global”), in February 2019 and the wholly-owned
subsidiaries of Khrysos Global, INXL Laboratories, Inc., a Florida
corporation (“INXL”) and INX Holdings, Inc., a Florida corporation
(“INXH”).
|
In the following text, the term “the Company” refers collectively
to the Company and its subsidiaries.
Basis of Presentation
The accompanying unaudited condensed consolidated financial
statements have been prepared in accordance with the rules and
regulations of the Securities and Exchange Commission (the “SEC”)
for interim financial information. Accordingly, certain information
and footnote disclosures, normally included in financial statements
prepared in accordance with generally accepted accounting
principles, have been condensed or omitted pursuant to such rules
and regulations.
Youngevity International, Inc. (the “Company”) consolidates all
wholly-owned subsidiaries. All significant intercompany accounts
and transactions have been eliminated in consolidation.
The condensed consolidated financial statements presented as of
June 30, 2020 and for the
three and six months ended June 30, 2020 and 2019 are unaudited. In the opinion of
management, these unaudited condensed consolidated financial
statements reflect all normal recurring and other adjustments
necessary for a fair presentation, and to make the financial
statements not misleading. These
condensed consolidated financial statements should be read in
conjunction with the audited consolidated financial statements
included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on
June 25, 2021. The results for
interim periods are not necessarily
indicative of the results for the entire year.
Segment Information
The Company has three reportable segments: direct selling,
commercial coffee, and commercial hemp. The direct selling segment
develops and distributes health and wellness products through its
global independent direct selling network also known as multi-level
marketing. The commercial coffee segment is engaged in coffee
roasting and distribution, specializing in gourmet coffee. The
commercial hemp segment manufactures proprietary systems to provide
end-to-end extraction and processing that allow for the conversion
of hemp feed stock into hemp oil and hemp extracts. The
determination that the Company has three reportable segments is based upon the
guidance set forth in Accounting Standards Codification (“ASC”)
Topic 280, “Segment
Reporting.”
During the three months ended
June 30, 2020, the Company derived
approximately 91.8% of its revenue from its direct selling segment,
6.8% of its revenue from its commercial coffee segment and 1.4%
from the commercial hemp segment. During the three months ended June 30, 2019, the Company derived
approximately 84.1% of its revenue from its direct selling segment,
15.2% of its revenue from its commercial coffee segment and 0.7%
from the commercial hemp segment.
During the six months ended
June 30, 2020, the Company derived
approximately 89.7% of its revenue from its direct selling segment,
9.2% of its revenue from its commercial coffee segment and 1.1%
from the commercial hemp segment. During the six months ended June 30, 2019, the Company derived
approximately 82.5% of its revenue from its direct selling segment,
17.0% of its revenue from its commercial coffee segment and 0.4%
from the commercial hemp segment.
Use of Estimates
The preparation of financial statements in conformity with
accounting principles generally accepted in the United States
(“GAAP”) requires the Company to make estimates and assumptions
that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenue and
expense for each reporting period. Estimates are used in
accounting for, among other things, allowances for doubtful
accounts, deferred taxes and related valuation allowances,
fair value of derivative liabilities, uncertain tax positions, loss
contingencies, fair value of options granted under the Company’s
stock-based compensation plan, fair value of assets and liabilities
acquired in business combinations, finance leases, asset
impairments, estimates of future cash flows used to evaluate
impairments, useful lives of property, equipment and intangible
assets, value of contingent acquisition debt, inventory
obsolescence, and sales returns.
Actual results may differ from
previously estimated amounts and such differences may be material to the consolidated financial
statements. Estimates and assumptions are reviewed
periodically, and the effects of revisions are reflected
prospectively in the period they occur.
Liquidity and Going Concern
The accompanying consolidated financial statements have been
prepared and presented on a basis assuming the Company will
continue as a going concern. The Company has sustained significant
net losses during the six months
ended June 30, 2020 and 2019 of approximately $10,331,000 and
$12,549,000, respectively. Net cash used in operating activities
was approximately $4,373,000 and $5,381,000 for the six months ended June 30, 2020 and 2019, respectively.
Management has assessed the Company’s ability to continue as a
going concern and concluded that additional capital will be
required during the twelve-months
subsequent to the filing date of this Quarterly Report on Form
10-Q. The timing of when the
additional capital will be required is uncertain and highly
dependent on factors discussed below. There can be no assurance that the Company will be able to
execute license or purchase agreements or to obtain equity or debt
financing, or on terms acceptable to it. Factors within and outside
the Company’s control could have a significant bearing on its
ability to obtain additional financing. As a result, management has
determined that there are material uncertainties that raise
substantial doubt upon the Company’s ability to continue as a going
concern.
The Company has and continues to take actions to alleviate the cash
used in operations. During the six
months ending June 30 2020, the
Company reported total revenue of approximately $68,523,000 a
decrease of approximately 13.7% compared to the same period a year
ago. The Company continues to focus on revenue growth, but the
Company cannot make assurances that revenues will grow.
Additionally, the Company has plans to make the necessary cost
reductions and to reduce non-essential expenses, including
international operations that are not performing well to help alleviate the
cash used in operating activities.
The outbreak of COVID-19 and
resulting pandemic resulted in significant contraction of economies
around the world and interrupted global supply chains as many
governments issued stay-at-home orders to combat COVID-19. The outbreak of COVID-19 also impacted the Company’s ability to
properly staff and maintain its domestic and international
warehousing operations due to stay-at-home orders issued within
various locations where the Company operates warehouse and shipping
operations. The Company took actions to mitigate the impact but
cannot assert that future stay-at-home orders or further
restrictive orders will not have an
impact on future operations. The Company experienced changes in
product mix demand, with demand increasing toward health-oriented
products and weakening for non-health related products. Such
changes in demand may have a
significant impact on revenues, margins and net operating profit in
the future. The outbreak also impacted the Company’s ability to
obtain some ingredients and packaging as well as ship products in
some markets. The Company’s supply chain and logistics incurred
some interruptions and cost impacts to date, and the Company could
experience more significant interruptions and cost impacts. The
Company’s suppliers of raw material and supplies have and could
continue to be impacted by geopolitical events, such as the war in
Ukraine, thus interrupting the Company’s supply chain.
Additionally, the Company’s customers may experience interruptions from other
suppliers that could cause a customer to delay or cancel orders.
These factors and other events have negatively impacted the
Company’s sales and operations and will likely continue to
negatively affect the Company’s business and financial results. The
Company is unable to predict the possible future effect on the
demand for products sold by the Company, and the related revenues,
margins and operating profit due to these events.
In addition, the outbreak of the COVID-19 coronavirus has disrupted the Company’s
operations due to absenteeism by infected or ill members of
management or other employees, or absenteeism by members of
management and other employees who elect not to come to work due to the illness
affecting others in the Company’s office or other workplace, or due
to quarantines. COVID-19 illness
could also impact members of the Company’s board of directors
resulting in absenteeism from meetings of the directors or
committees of directors and making it more difficult to convene the
quorums of the full board of directors or its committees needed to
conduct meetings for the management of the Company’s affairs.
The Company continues to seek and obtain equity or debt financing
on terms that are acceptable to the Company. Depending on market
conditions, there can be no
assurance that additional capital will be available when needed or
that, if available, it will be obtained on terms favorable to the
Company or to its stockholders.
These financial statements have been prepared on a going concern
basis, which asserts the Company has the ability in the near term
to continue to realize its assets and discharge its liabilities and
commitments in a planned manner giving consideration to the above
and expected possible outcomes. The financial statements do
not include any adjustments that
might be necessary from the outcome of this uncertainty. Within the
current operating environment due to the declared national
emergency, related to COVID 19
combined with the management plans described above the Company
cannot assert that the doubt of the Company’s ability to continue
as a going concern has been substantially alleviated. Conversely,
if the going concern assumption is not appropriate, adjustments to the carrying
amounts of the Company’s assets, liabilities, revenues, expenses
and balance sheet classifications may be necessary, and these adjustments could
be material.
Revenue Recognition
The Company recognizes revenue from product sales when the
following five steps are completed:
i) Identify the contract with the customer; ii) Identify the
performance obligations in the contract; iii) Determine the
transaction price; iv) Allocate the transaction price to the
performance obligations in the contract; and v) Recognize revenue
when (or as) each performance obligation is satisfied.
Revenue is recognized upon transfer of control of promised products
or services to customers in an amount that reflects the
consideration the Company expects to receive in exchange for those
products or services. The Company enters into contracts that can
include various combinations of products and services, which are
generally capable of being distinct and accounted for as separate
performance obligations. Revenue is recognized net of allowances
for returns and any taxes collected from customers, which are
subsequently remitted to governmental authorities.
The transaction price for all sales is based on the price reflected
in the individual customer’s contract or purchase order.
Variable consideration has not been
identified as a significant component of the transaction price for
any of our transactions.
Independent distributors receive compensation which is recognized
as distributor compensation in the Company’s consolidated
statements of operations. Due to the short-term nature of the
contract with the customers, the Company accrues all distributor
compensation expense in the month earned and pays the compensation
the following month.
The Company also charges fees to become a distributor, and earn a
position in the network genealogy, which are recognized as revenue
in the period received. The Company’s distributors are required to
pay a one-time enrollment fee and
receive a welcome kit specific to that country or region that
consists of forms, policy and procedures, selling aids, access to
our distributor website and a genealogy position with no down line distributors.
The Company has determined that most contracts will be completed in
less than one year. For those
transactions where all performance obligations will be satisfied
within one year or less, the
Company is applying the practical expedient outlined in ASC
606-10-32-18. The
practical expedient allows the Company not to adjust promised consideration for the
effects of a significant financing component if the Company expects
at contract inception the period between when the Company transfers
the promised good or service to a customer and when the customer
pays for that good or service will be one year or less. For those transactions that
are expected to be completed after one year, the Company has assessed that there
are no significant financing
components because any difference between the promised
consideration and the cash selling price of the good or service is
for reasons other than the provision of financing.
Revenue recognition by segment is as follows:
Direct Selling. Direct distribution sales are made
through the Company’s network (direct selling segment), which is a
web-based global network of customers and distributors. The
Company’s independent sales force markets a variety of products to
an array of customers, through friend-to-friend marketing and
social networking. The Company considers itself to be an e-commerce
company whereby personal interaction is provided to customers by
its independent sales network. Sales generated from direct
distribution includes; health and wellness, beauty product and skin
care, scrap booking and story booking items, packaged food products
and other service-based products.
Revenue is recognized when the Company satisfies its performance
obligations under the contract. The Company recognizes revenue by
transferring the promised products to the customer, with revenue
recognized at shipping point, the point in time the customer
obtains control of the products. The majority of the Company’s
contracts have a single performance obligation and are short term
in nature. Sales taxes in domestic and foreign jurisdictions are
collected from customers and remitted to governmental authorities,
all at the local level, and are accounted for on a net basis and
therefore are excluded from revenues.
Commercial Coffee – Roasted Coffee. The
Company engages in the commercial sale of roasted coffee through
CLR, which is sold under a variety of private labels through major
national sales outlets and to customers including cruise lines and
office coffee service operators, and under its own Café La Rica
brand, Josie’s Java House Brand, Javalution brands and Café Cachita
as well as through its distributor network within the direct
selling segment.
Revenue is recognized when the title and risk of loss is passed to
the customer under the terms of the shipping arrangement,
typically, FOB shipping point. At this point the customer has a
present obligation to pay, takes physical possession of the
product, takes legal title to the product, bears the risks and
rewards of ownership, and as such, revenue will be recognized at
this point in time. Sales taxes in domestic and foreign
jurisdictions are collected from customers and remitted to
governmental authorities, all at the local level, and are accounted
for on a net basis and therefore are excluded from revenues.
Commercial Coffee – Green Coffee.
The commercial coffee segment includes the sale of green coffee
beans, which are sourced from the Nicaraguan rainforest.
Revenue is recognized when the title and risk of loss is passed to
the customer under the terms of the shipping arrangement,
typically, FOB shipping point. At this point the customer has a
present obligation to pay, takes physical possession of the
product, takes legal title to the product, bears the risks and
rewards of ownership, and as such, revenue will be recognized at
this point in time. Revenues where the Company sells green coffee
beans that it has milled and where the Company has determined it is
the agent with regard to the green coffee beans is recorded at net
or recorded to reflect only the milling services provided. Sales
taxes in domestic and foreign jurisdictions are collected from
customers and remitted to governmental authorities, all at the
local level, and are accounted for on a net basis and therefore are
excluded from revenues.
Commercial Hemp. In the commercial hemp segment, the
Company develops, manufactures, and sells equipment and related
services to customers which enable them to extract CBD oils from
hemp stock. The Company provides hemp growers, feedstock suppliers,
and CBD crude oil producers the use of equipment, intellectual
capital, production consultancy, tolling services, and wholesale
CBD channel sales capabilities. The Company is also engaged in
hemp-based CBD extraction technology including tolling processing
which converts hemp crude oil to hemp extracts such as full
spectrum distillate, and cannabinoid isolate (CBD, cannabigerol or
CBG, cannabinol or CBN). The Company offers customers turnkey
manufacturing solutions in extraction services and end-to-end
processing systems. In addition, the Company provides a broad range
of capabilities in regard to formulation, quality control, and
testing standards with our CBD products, including potency analysis
for its supply partners of hemp derived CBD products. The Company
follows all guidelines for Current Good Manufacturing Practices
(“CGMP”) and our hemp extracts are processed, produced, and tested
throughout the manufacturing process to confirm that the
cannabinoid content meets strict company standards.
Revenue is recognized when the title and risk of loss is passed to
the customer under the terms of the shipping arrangement,
typically, FOB shipping point. At this point the customer has a
present obligation to pay, takes physical possession of the
product, takes legal title to the product, bears the risks and
rewards of ownership, and as such, revenue will be recognized at
this point in time. Sales taxes in domestic and foreign
jurisdictions are collected from customers and remitted to
governmental authorities, all at the local level, and are accounted
for on a net basis and therefore are excluded from revenues.
Contract Balances. Timing of revenue recognition
may differ from the timing of
invoicing to customers. The Company records contract assets when
performance obligations are satisfied prior to invoicing.
Contract liabilities are reflected as deferred revenues and
customer deposits in accrued expenses, deferred revenue, other
current liabilities and other long-term liabilities on the
Company’s consolidated balance sheets. Contract liabilities relate
to payments invoiced or received in advance of completion of
performance obligations and are recognized as revenue upon the
fulfillment of performance obligations. The Company recognizes
deferred revenue in its direct selling, commercial coffee and
commercial coffee segments.
In January 2020, the Company
introduced a rewards program in the direct selling segment where
its distributors earn points awards that can be redeemed for the
future product purchases. These points awards are earned by the
distributors through the purchase of products or through actions
and participation in non-product purchase activities. The Company
records the points earned through the purchase of product by
reducing revenue and creates the liability at the point of
purchase. Award points earned through non-product purchasing
activities are recorded as marketing expenses and creates the
liability at the time the distributor performs the non-revenue
activity.
The deferred revenue related to Heritage Maker’s product line
obligation for points purchased by customers represents cash
payments received that have not yet
been redeemed for product. Revenue is recognized when customers
redeem the points, and the product is shipped. Deferred revenues
related to pre-enrollment in conventions and distributor events
primarily related to the Company’s 2020 events. The Company does not recognize revenue until the conventions
or distributor events have occurred.
The Company also records deferred revenue within its direct
selling, commercial coffee and commercial hemp segments related to
payments made by customers for unshipped orders.
Deferred costs relate to Heritage Makers prepaid commissions are
recorded in prepaid expenses and other current assets on the
Company’s consolidated balance sheets and recognized in expense at
the time the related revenue is recognized.
Plantation Costs
The Company’s commercial coffee segment includes the results of
Siles, which is comprised of (i) a 500-acre coffee plantation and
(ii) a dry-processing facility located on 26 acres, both of which
are located in Matagalpa, Nicaragua. Siles is a wholly-owned
subsidiary of CLR, and the results of CLR include the
depreciation and amortization of capitalized costs, development and
maintenance and harvesting costs of Siles. In accordance with
GAAP, plantation maintenance and harvesting costs for commercially
producing coffee farms are charged against earnings when
sold. Deferred harvest costs accumulate and are capitalized
throughout the year and are expensed over the remainder of the year
as the coffee is sold. The difference between actual harvest costs
incurred and the amount of harvest costs recognized as expense is
recorded as either an increase or decrease in deferred harvest
costs, which is reported as an asset and included with prepaid
expenses and other current assets in the condensed consolidated
balance sheets. Once the harvest is complete, the harvest costs are
then recognized as the inventory value. There were no deferred
costs associated with the harvest at June 30, 2020. Deferred costs associated with
the harvest at December 31, 2019
were approximately $350,000.
Stock-based Compensation
The Company accounts for stock-based compensation in accordance
with ASC Topic 718,
“Compensation – Stock Compensation,” which
establishes accounting for equity instruments exchanged for
services from employees and non-employees. Under such provisions,
cost is measured at the grant date, based on the calculated fair
value of the award, and is recognized as an expense net of
forfeitures, under the straight-line method, over the vesting
period of the equity grant. Forfeitures are recorded as they
occur.
The Company uses the Black-Scholes to estimate the fair value of
stock options. The use of a valuation model requires the Company to
make certain assumptions with respect to selected model inputs.
Expected volatility is calculated based on the historical
volatility of the Company’s stock price over the expected term
of the option. The expected life is based on the contractual
life of the option and expected employee exercise and post-vesting
employment termination behavior. The risk-free interest rate is
based on U.S. Treasury zero-coupon
issues with a remaining term equal to the expected life assumed at
the date of the grant.
Income Taxes
The Company accounts for income taxes in accordance with ASC
Topic 740, “Income
Taxes,” under the asset and liability method which
includes the recognition of deferred tax assets and liabilities for
the expected future tax consequences of events that have been
included in the condensed consolidated financial statements. Under
this approach, deferred taxes are recorded for the future tax
consequences expected to occur when the reported amounts of assets
and liabilities are recovered or paid. The provision for income
taxes represents income taxes paid or payable for the current year
plus the change in deferred taxes during the year. Deferred taxes
result from differences between the financial statement and tax
basis of assets and liabilities and are adjusted for changes in tax
rates and tax laws when changes are enacted. The effects of future
changes in income tax laws or rates are not anticipated.
Income taxes for the interim periods are computed using the
effective tax rates estimated to be applicable for the full fiscal
year, as adjusted for any discrete taxable events that occur during
the period.
The Company files income tax returns in the U.S. on a federal basis
and in many U.S. state and foreign jurisdictions. Certain tax years
remain open to examination by the major taxing jurisdictions to
which the Company is subject.
Commitments and Contingencies
The Company is from time to time, the subject of claims and suits
arising out of matters related to the Company’s business. The
Company is party to litigation at the present time and may become party to litigation in the future.
In general, litigation claims can be expensive, and time consuming
to bring or defend against and could result in settlements or
damages that could significantly affect financial results. It is
not possible to predict the final
resolution of the current litigation to which the Company is party
to, and the impact of certain of these matters on the Company’s
business, results of operations, and financial condition could be
material. Regardless of the outcome, litigation has adversely
impacted the Company’s business because of defense costs, diversion
of management resources and other factors.
Basic and Diluted Net Loss Per Share
Basic loss per share is computed by dividing net loss attributable
to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted loss per share is
computed by dividing net loss attributable to common stockholders
by the sum of the weighted-average number of common shares
outstanding during the period and the weighted-average number of
dilutive common share equivalents outstanding during the period,
using the treasury stock method. Dilutive common share equivalents
are comprised of stock options, restricted stock, warrants,
convertible preferred stock and common stock associated with the
Company’s convertible notes based on the average stock price for
each period using the treasury stock method. Potentially dilutive
shares are excluded from the computation of diluted net loss per
share when their effect is anti-dilutive.
In periods where a net loss is presented, all potentially dilutive
securities are anti-dilutive and are excluded from the computation
of diluted net loss per share. Potentially dilutive securities for
the periods ended June 30, 2020 and
2019 were 11,793,391 and
12,731,372, respectively.
|
|
June 30,
2020
|
|
|
June 30,
2019
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
Warrants
|
|
|
6,413,182 |
|
|
|
6,903,874 |
|
Preferred stock conversions
|
|
|
18,876 |
|
|
|
275,604 |
|
Principal conversions on convertible notes
|
|
|
312,571 |
|
|
|
410,592 |
|
Stock options
|
|
|
4,610,152 |
|
|
|
4,716,302 |
|
Restricted stock units
|
|
|
438,610 |
|
|
|
425,000 |
|
Total
|
|
|
11,793,391 |
|
|
|
12,731,372 |
|
The calculation of diluted loss per share requires that, to the
extent the average market price of the underlying shares for the
reporting period exceeds the exercise price of the warrants and the
presumed exercise of such securities are dilutive to loss per share
for the period, an adjustment to net loss used in the calculation
is required to remove the change in fair value of the warrants, net
of tax from the numerator for the period. Likewise, an adjustment
to the denominator is required to reflect the related dilutive
shares, if any, under the treasury stock method. During the
three and six months ended June 30, 2019, the Company recorded net of
tax gain of $357,000 and $1,478,000, respectively, on the valuation
of the warrant derivative liability which had a dilutive impact on
the loss per share.
|
|
Three Months Ended
June 30,
|
|
|
Six Months Ended
June 30,
|
|
|
|
2020
|
|
|
2019
|
|
|
2020
|
|
|
2019
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
|
(unaudited) |
|
|
(unaudited) |
|
Loss per Share – Basic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator for basic loss per share
|
|
$ |
(4,903,000 |
)
|
|
$ |
(317,000 |
)
|
|
$ |
(11,073,000 |
)
|
|
$ |
(12,591,000 |
)
|
Denominator for basic loss per share
|
|
|
31,882,762 |
|
|
|
29,133,150 |
|
|
|
31,098,874 |
|
|
|
28,359,660 |
|
Loss per common share – basic
|
|
$ |
(0.15 |
)
|
|
$ |
(0.01 |
)
|
|
$ |
(0.36 |
)
|
|
$ |
(0.44 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per Share – Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator for basic loss per share
|
|
$ |
(4,903,000 |
)
|
|
$ |
(317,000 |
)
|
|
$ |
(11,073,000 |
)
|
|
$ |
(12,591,000 |
)
|
Adjust: Fair value of dilutive warrants outstanding
|
|
|
- |
|
|
|
(357,000 |
)
|
|
|
- |
|
|
|
(1,478,000 |
)
|
Numerator for dilutive loss per share
|
|
$ |
(4,903,000 |
)
|
|
$ |
(674,000 |
)
|
|
$ |
(11,073,000 |
)
|
|
$ |
(14,069,000 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for basic loss per share
|
|
|
31,882,762 |
|
|
|
29,133,150 |
|
|
|
31,098,874 |
|
|
|
28,359,660 |
|
Plus: Incremental shares underlying “in the money” warrants
outstanding
|
|
|
- |
|
|
|
224,197 |
|
|
|
- |
|
|
|
340,635 |
|
Denominator for dilutive loss per share
|
|
|
31,882,762 |
|
|
|
29,357,347 |
|
|
|
31,098,874 |
|
|
|
28,700,295 |
|
Loss per common share – diluted
|
|
$ |
(0.15 |
)
|
|
$ |
(0.02 |
)
|
|
$ |
(0.36 |
)
|
|
$ |
(0.49 |
)
|
Recently Issued and Adopted Accounting
Pronouncements
The Company does not believe that
any recently issued effective pronouncements, or pronouncements
issued but not yet effective, if
adopted, would have a material effect on the Company’s financial
statements. During the six months
ended June 30, 2020, the Company
did not adopt any accounting
pronouncements.
Note 2. Acquisitions and
Business Combinations
During 2019, the Company entered
into two acquisitions which are
detailed below. The acquisitions were conducted to allow the
Company to enter into the hemp market and expand the Company’s
distributor network within the direct selling segment, enhance and
expand its product portfolio, and diversify its product mix. As a
result of the Company’s business combinations, the Company’s
distributors and customers will have access to the acquired
company’s products and acquired company’s distributors and
customers will gain access to products offered by the
Company.
As such, the major purpose for the business combinations was to
increase revenue and profitability. The acquisitions were
structured as asset purchases which resulted in the recognition of
certain intangible assets.
During the six months ended
June 30, 2020, the Company did
not have any acquisitions.
2019 Acquisitions
BeneYOU
On October 31, 2019, the Company
entered into an asset purchase agreement with an effective date of
November 1, 2019, with BeneYOU,
LLC, a Utah limited liability company (“BeneYOU”), and Ryan
Anderson (the “BeneYOU Representing Party”), for the Company to
acquire certain assets of BeneYOU to including all of the
outstanding equity of BeneYOU Holding, LLC, a Utah limited
liability company (“BeneYOU Holding”), collectively “BeneYOU”. In
accordance with the asset purchase agreement, the Company also
acquired BeneYOU’s customer and distributor organization lists, all
intellectual property, product formulations, products, product
packaging, product registrations, licenses, marketing materials,
sales tools and swag, and all saleable inventory. BeneYOU’s
flagship brand Jamberry has an extensive line of nail products with
a core competency in social selling, and two other brands including Avisae which
focuses on the gut health and the M.Global brand of products that
includes hydration products.
The Company is obligated to make monthly payments based on a
percentage of the BeneYOU distributor revenue derived from sales of
the Company’s products and a percentage of royalty revenue derived
from sales of BeneYOU products until the earlier of the date that
is ten years from the closing date
or such time as the Company has paid to BeneYOU aggregate cash
payments of the BeneYOU distributor revenue and royalty revenue
equal to the maximum aggregate purchase price of $3,500,000. In
addition, the Company paid an acquisition liability payment of
$200,000 on the closing date, which reduced the maximum aggregate
purchase price to $3,300,000.
The contingent consideration’s estimated fair value at the date of
acquisition was approximately $2,648,000 as determined by
management using a discounted cash flow methodology. The
acquisition related costs, such as legal costs and other
professional fees were minimal and expensed as incurred.
The purchase agreement contains customary representations,
warranties and covenants of the Company, BeneYOU and the BeneYOU
Representing Party. Subject to certain customary limitations the
BeneYOU Representing Party have agreed to indemnify the Company and
BeneYOU against certain losses related to, among other things,
breaches of the BeneYOU Representing Party’s representations and
warranties, certain specified liabilities and the failure to
perform covenants or obligations under the purchase agreement.
The Company recorded the fair value at the date of acquisition of
the acquired tangible and intangible assets and liabilities as
follows (in thousands):
Contingent consideration
|
|
$ |
2,648 |
|
Aggregate purchase price
|
|
$ |
2,648 |
|
The following table summarizes the fair values of the assets
acquired and liabilities assumed in November 2019 (in thousands):
Current assets (excluding inventory)
|
|
$ |
408 |
|
Inventory (net of $469 reserve)
|
|
|
441 |
|
Trademarks and trade name
|
|
|
343 |
|
Distributor organization
|
|
|
1,175 |
|
Customer relationships
|
|
|
44 |
|
Non-compete agreement
|
|
|
277 |
|
Goodwill
|
|
|
669 |
|
Current liabilities
|
|
|
(709 |
)
|
Net assets acquired
|
|
$ |
2,648 |
|
The reported fair value of intangible assets acquired of $1,839,000
was determined through the use of a third-party valuation firm using various
income and cost approach methodologies. Specifically, the
intangibles identified in the acquisition were trademarks and trade
name, distributor organization, customer relationships and
non-compete agreement and are being amortized over their estimated
useful life of 5 years, 9 years, 5 years and 4 years, respectively.
The straight-line method is being used and is believed to
approximate the timeline within which the economic benefit of the
underlying intangible asset will be realized.
Goodwill of $669,000 was recognized as the excess purchase price
over the acquisition-date fair value of net assets acquired.
Goodwill is estimated to represent the synergistic values expected
to be realized from the combination of the two businesses. The goodwill is expected to
be deductible for tax purposes.
The pro-forma effect assuming the business combination with BeneYOU
discussed above had occurred at the beginning of 2019 is not
presented as the information was not available.
Khrysos Global, Inc.
On February 12, 2019, the Company
and KII entered into an asset and equity purchase agreement (the
“AEPA”) with Khrysos Global, and Leigh Dundore and Dwayne Dundore
(collectively, the “Khrysos Representing Party”), for KII to
acquire substantially all the assets of Khrysos Global and all the
outstanding equity of INXL and INXH. The collective business
manufactures proprietary systems to provide end-to-end extraction
and processing that allow for the conversion of hemp feed stock
into hemp oil and hemp extracts.
The aggregate consideration payable for the assets of Khrysos
Global and the equity of INXL and INXH of $16,000,000 is to be paid
as set forth under the terms of the AEPA and allocated between
Khrysos Global and Leigh Dundore in such manner as they determine
at their discretion.
At closing, Khrysos Global and the Khrysos Representing Party
received an aggregate of 1,794,972 shares of the Company’s common
stock which had a value of $14,000,000 for the purposes of the AEPA
and $500,000 in cash. The fair value of the common stock calculated
as part of the acquisition valuation was approximately $14,000,000.
In addition, the Company agreed to pay the sellers $1,500,000 in
cash towards the AEPA of which $1,000,000 was paid to Khrysos
Global and the Khrysos Representing Party during 2019. The remaining cash payment of $500,000
was not paid as of the filing date
herewith as the Company continues to evaluate the terms of the
acquisition agreement in conjunction with the termination of the
KII President, noted below. At June 30,
2020 and December 31, 2019,
the Company’s remaining liability of $500,000, was outstanding and
recorded as accrued expenses on the condensed consolidated balance
sheet.
The AEPA contains customary representations, warranties and
covenants of the Company, Khrysos Global and the Khrysos
Representing Party. Subject to certain customary limitations
Khrysos Global and the Khrysos Representing Party have agreed to
indemnify the Company and KII against certain losses related to,
among other things, breaches of the Khrysos Representing Party’s
representations and warranties, certain specified liabilities and
the failure to perform covenants or obligations under the AEPA.
In conjunction with the acquisition and organization of KII, the
Company retained Dwayne Dundore as President of KII. Previously
agreed-upon equity compensation in the form of warrants that was to
be provided as part of the closing to Dwayne Dundore by the Company
were mutually terminated. Effective September 17, 2020, Dwayne Dundore was
no longer employed with KII or the
Company.
The Company has estimated fair value at the date of acquisition of
the acquired tangible and intangible assets and liabilities as
follows (in thousands):
Present value of cash consideration
|
|
$ |
1,894 |
|
Estimated fair value of common stock issued
|
|
|
14,000 |
|
Aggregate purchase price
|
|
$ |
15,894 |
|
The following table summarizes the estimated and as adjusted fair
values of the assets acquired and liabilities assumed in February 2019 (in thousands):
Current assets
|
|
$ |
636 |
|
Inventory
|
|
|
1,264 |
|
Property, plant and equipment
|
|
|
1,133 |
|
Trademarks and trade name
|
|
|
1,876 |
|
Customer-related intangible
|
|
|
5,629 |
|
Non-compete intangible
|
|
|
956 |
|
Goodwill
|
|
|
6,831 |
|
Current liabilities
|
|
|
(1,904 |
)
|
Notes payable
|
|
|
(527 |
)
|
Net assets acquired
|
|
$ |
15,894 |
|
The reported fair value of intangible assets acquired in the amount
of $8,461,000 was determined through the use of a third-party valuation firm using various
income and cost approach methodologies. Specifically, the
intangibles identified in the acquisition were trademarks and trade
name, customer relationships and non-compete agreement. The
trademarks and trade name, customer relationships and
non-compete agreement are being amortized over their estimated
useful life of 8 years, 4 years and 6 years, respectively. The
straight-line method is being used and is believed to approximate
the timeline within which the economic benefit of the underlying
intangible asset will be realized. In connection with the Company’s
annual impairment test in 2019, the
net book value of intangible assets of $8,461,000 was determined to
be impaired. (See Note 5)
Goodwill of $6,831,000 was recognized as the excess purchase price
over the acquisition-date fair value of net assets acquired. In
connection with the Company’s annual impairment test in 2019, the full amount of goodwill recognized
was determined to be impaired.
The costs related to the acquisition are included in legal and
accounting fees and were expensed as incurred.
The pro-forma effect assuming the business combination with KII
discussed above had occurred at the beginning of 2019 is not
presented as the information was not available.
- 17-
Note 3. Related
Party Transactions
Hernandez, Hernandez, Export Y Company and H&H Coffee
Group Export Corp.
The Company’s wholly-owned subsidiary, CLR, is associated with
Hernandez, Hernandez, Export Y Company (“H&H”), a Nicaragua
company, through sourcing arrangements to procure Nicaraguan grown
green coffee beans. As part of the 2014 Siles acquisition, CLR engaged the
owners of H&H, Alain Piedra Hernandez (“Mr. Hernandez”) and
Marisol Del Carmen Siles Orozco (“Ms. Orozco”), as employees to
manage Siles.
H&H is a sourcing agent that purchases raw green coffee beans
from the local producers in Nicaragua and supplies CLR’s mill with
unprocessed green coffee for processing. CLR does not have a direct relationship with the local
producers and is dependent on H&H to negotiate agreements with
local producers for the supply and provide to CLR’s mill raw
unprocessed green coffee to CLR’s mill in a timely and efficient
manner. Substantially all the green coffee processed through the
Siles mill was coffee assigned to CLR for processing. During the
three and six months ended June 30, 2019, CLR’s largest customer for
green coffee beans was H&H Coffee Group Export Corp. (“H&H
Export”), a company related to H&H. In consideration for
H&H’s sourcing of green coffee for processing within CLR’s
mill, CLR and H&H share in the green coffee profit from milling
operations.
During the three and six months ended June 30, 2020, CLR had purchases from H&H
of approximately $784,000 and $1,775,000, respectively, and had
purchases from H&H Export of $200,000 and $471,000,
respectively. CLR made purchases of unprocessed green coffee from
H&H of approximately $252,000 and $2,828,000 during the
three and six months ended June 30, 2019.
During the three months ended
June 30, 2020 and 2019, CLR recorded net revenues from H&H
Export of approximately $156,000 and $1,561,000, respectively, and
$324,000 and $6,387,000, respectively, for the six months then ended.
At June 30, 2020 and December 31, 2019, CLR’s accounts receivable
balances for customer related revenue from H&H Export were
$8,289,000 and $8,707,000, respectively, of which the full amounts
were past due at the corresponding periods. As a result, the
Company reserved $7,871,000 as bad debt related to the accounts
receivable balances for both periods, which was net of collections
through December 31, 2020.
At June 30, 2020, the following
balances were recorded from transactions with H&H:
|
●
|
Prepaid expenses and other current assets of approximately
$1,100,000 related to green coffee acquisition,
|
|
●
|
accounts payable of $230,000 related to billings for freight and
other charges by H&H,
|
|
●
|
accrued expenses of $250,000 primarily related to mill operation
costs, and
|
|
●
|
accrued expenses offset of $712,000 related to overpaid cost of
green coffee.
|
H&H Finance Agreement
In March 2020, CLR entered into a
Finance, Security and ARAP Monetization Agreement (the “H&H
Finance Agreement”) with H&H Export Y CIA. LTDA and
H&H Export (collectively, the “H&H Export Group”). The
H&H Finance Agreement was designed to provide the Company with
access to a continued supply of unprocessed green coffee beans for
the 2020 growing season and a
solution for funding of the continued operations of the Company’s
green coffee distribution business. Pursuant to the Agreement, the
H&H Export Group had agreed to allow a Nicaraguan agency (the
“Nicaraguan Agency”) to advance on behalf of the H&H Export
Group, approximately $22,000,000 of the $30,100,000 of accounts
receivable owed by H&H Export to CLR for its purchase of
processed green coffee during the 2019 season. The Nicaraguan Agency also
entered into a $46,500,000 credit facility with the H&H Export
Group to provide funding for the H&H Export Group’s future
coffee purchases of unprocessed green coffee from independent
producers. Of the 2020 sales
amounts to be billed by CLR for future coffee purchases of
processed coffee, CLR was to be paid an additional amount, at a
rate of $0.225 per pound of processed green coffee shipped to
customers, to be applied to the remaining outstanding 2019 accounts receivable balance owed by
H&H Export to CLR. Until such time as the entire accounts
receivable balance is paid in full, H&H Export has agreed
not take any profit interest.
However, given the COVID crisis’ impact on the 2020 growing season and the continued delay
in full payment of the 2020
receivable balances, management considered H&H Export accounts
receivable impaired at June 30,
2020. Subsequent to the H&H Finance Agreement, CLR adopted
the recognition of recording revenues at net for sales between CLR
and H&H Export.
In March 2021, CLR entered into a
master relationship agreement with the owners of H&H in order
to memorialize the various agreements and modifications to those
agreements. (See Note 13)
H&H Export Note Receivable
In December 2018, CLR advanced
$5,000,000 to H&H Export to provide services in support of a
five-year contract for the sale and
processing of 41 million pounds of
green coffee beans on an annual basis. The services include
providing hedging and financing opportunities to producers and
delivering harvested coffee to the Company’s mills. In
March 2019, this advance was
converted to a $5,000,000 loan agreement as a note receivable and
bears interest at 9.00% per annum and is due and payable by H&H
Export at the end of each year’s harvest season, but no later than October 31 for any harvest year. In
October 2019, CLR and H&H
Export amended the March 2019
agreement in terms of the maturity date such that all outstanding
principal and interest was due and payable at the end of the
2020 harvest (or when the
2020 season’s harvest was exported
and collected), but never to be later than November 30, 2020.
Management reviewed the security against the loan and the impact of
the underlying COVID crisis and determined that the full amount of
the note receivable including interest of approximately $5,565,000
and $5,340,000 was not collected at
June 30, 2020 and December 31, 2019, respectively, and
therefore the full amounts were recognized as an allowance for
collectability at the end of each respective period.
Mill Construction Agreement between CLR and
H&H
In January 2019, to accommodate
CLR’s green coffee purchase contract, CLR entered into a mill
construction agreement with H&H and H&H Export, Mr.
Hernandez and Ms. Orozco (together with H&H, collectively
referred to as the “Nicaraguan Partner”), pursuant to which the
Nicaraguan Partner agreed to transfer a 45-acre tract of land in
Matagalpa, Nicaragua (the “Matagalpa Property”) to be owned 50% by
the Nicaraguan Partner and 50% by CLR. In consideration for the
land acquisition the Company issued to H&H Export, 153,846
shares of common stock. The fair value of the shares issued was
$1,200,000 and was based on the stock price on the date of issuance
of the shares. In addition, the Nicaraguan Partner and CLR agreed
to contribute $4,700,000 each toward construction of a processing
plant, office, and storage facilities on the Matagalpa Property
(collectively the “Matagalpa Mill”) for processing coffee in
Nicaragua. The addition of the mill will accommodate CLR’s green
coffee contract commitments.
For the three months ended
June 30, 2020 and 2019, CLR made payments of approximately
$500,000 and $800,000, respectively, towards the Matagalpa mill
project and $800,000 and $2,150,000, respectively, for the
six months then ended.
At June 30, 2020, CLR contributed a
total of $3,850,000 towards the construction of the Matagalpa mill
project, which is included in construction in process within
property and equipment, net on the Company’s consolidated balance
sheets, and paid a total of $597,000 for operating equipment. At
June 30, 2020, the Nicaraguan
Partner contributed a total of $2,528,000 towards the Matagalpa
Mill project. At the filing date of this Quarterly Report on Form
10-Q, the Matagalpa Mill was still
incomplete for total operations.
In January 2019, the Company issued
295,910 shares of common stock to H&H Export to pay for certain
working capital, construction and other payables. In connection
with the issuance, the Company over issued 121,649 shares of common
stock, resulting in the net issuance of common stock to settle
payables of 174,261 shares. H&H Export agreed to reimburse CLR
for the over issuance of the 121,649 shares of common stock in
cash. At June 30, 2020 and
December 31, 2019, the value of the
shares was approximately $173,000 and $397,000, respectively, based
on the stock price at the respective periods. Management reviewed
the amount due in conjunction with the impact of the underlying
COVID crisis and has determined that the full receivable balances
were more than likely to be uncollected at June 30, 2020 and December 31, 2019, and therefore the full
amount was recognized as an allowance for collectability at the
respective periods.
Amended Operating and Profit-Sharing Agreement between CLR
and H&H
In January 2019, CLR entered into
an amendment to the March 2014
operating and profit-sharing agreement with the owners of H&H.
In addition, CLR and H&H, Mr. Hernandez and Ms. Orozco
restructured their profit-sharing agreement in regard to profits
from green coffee sales and processing that increased CLR’s profit
participation by an additional 25%. Under the new terms of the
agreement with respect to profit generated from green coffee sales
and processed from La Pita or the Matagalpa Mill, now will provide
for a split of profits of 75% to CLR and 25% to the Nicaraguan
Partner, after certain conditions are met. Profit-sharing
income for the three and six months ended June 30, 2020 was approximately $96,000 and
$211,000, respectively. The profit-sharing expense for the
three and six months ended June 30, 2019 was approximately $225,000 and
$468,000, respectively.
Joint Venture Agreement in Nicaragua for Hemp Processing
Center between the CLR and KII and Nicaraguan partner
In April and July 2020, CLR and KII (the U.S. Partners)
entered into agreements (the “Hemp Joint Venture Agreements”) with
H&H Export and Fitracomex, Inc. (“Fitracomex”) (collectively
“The Nicaraguan JV Partners”) and established the Nicaraguan Hemp
Grow and Extractions Group joint venture (the “Hemp Joint
Venture”). Fitracomex is indirectly related the Company due to its
relationship with H&H and is being treated as a related
party.
In accordance with the terms of the Hemp Joint Venture Agreements,
H&H Export will contribute the 2,200-acre Chaguitillo Farms in
Sebaco-Matagalpa, Nicaragua which will be owned by H&H Export
and the U.S. Partners on a 50/50
basis separate from the Hemp Joint Venture should the Hemp Joint
Venture determine to sell the land in the future.
The Nicaraguan JV Partners will contribute the excavation and
preparation for hemp growth of the 2,200 acres, installation of electrical
service, and the construction of 45,000 square feet of buildings to be used
for office, processing, storage, drying and green house space.
The U.S. Partners will contribute all the necessary extraction
equipment to convert hemp to crude oil and will also provide the
feminized hemp seeds for the pilot grow program, along with their
expertise in the hemp business. The U.S. Partners will also provide
all necessary working capital as required.
In April 2020, the Company issued
1,500,000 shares of restricted common stock to Fitracomex in
accordance with the Hemp Joint Venture Agreements. The fair value
of the shares at issuance was approximately $2,490,000. The Company
also agreed to issue warrants to Fitracomex for the purchase
5,000,000 shares of the Company’s common stock at an exercise price
of $1.50, exercisable for a term of five years after completion of
the construction and upon the approval of the Company’s
stockholders. At December 31, 2020,
the Company reserved the full amount of the investment issued to
Fitracomex.
The U.S. Partners and H&H Export will serve as the managing
partners and all business decisions will require prior consent and
agreement of both parties. The net profits and net losses for each
fiscal period shall be allocated twenty five percent to the
Nicaraguan JV Partners and seventy five percent to the U.S.
Partners. At the filing date of this Quarterly Report on Form
10-Q, the Hemp Joint Venture is
currently being assessed for changing market conditions related to
the hemp industry, and as a result of the fluctuating indicators
the Company is considering the timing of entering the market space
in regard to the launch of this project.
Other Agreements between CLR, H&H and H&H
Export
In January 2019, H&H Export
sold to CLR its espresso brand Café Cachita in consideration of the
issuance of 100,000 shares of the Company’s common stock. The
shares of common stock issued were valued at $7.50 per share.
In May 2017, CLR entered a
settlement agreement, as amended, with Mr. Hernandez who was issued
a warrant for the purchase of 75,000 shares of the Company’s common
stock at a price of $2.00 with an expiration date of three years, in lieu of an
obligation due from CLR to H&H as relates to a sourcing and
supply agreement with H&H and H&H Export. The warrants were
outstanding at December 31, 2019
and expired in May 2020.
Other Related Party Transactions
Richard Renton
Richard Renton was a member of the board of directors until
February 11, 2020 and owns WVNP,
Inc., a supplier of certain inventory items sold by the
Company. The Company made purchases from WVNP Inc. of
approximately $56,000 during the three months ended March 31, 2020. The Company made purchases
from WVNP Inc. of $103,000 and $111,000 for the three and six
months ended June 30, 2019,
respectively. In addition, Mr. Renton is a distributor of the
Company and was paid distributor commissions of $81,000 for the
three months ended March 31, 2020.
Carl Grover (Estate of Carl Wilford
Grover)
Mr. Grover was the sole beneficial owner of in excess of 5% of the Company’s outstanding common shares
at June 30, 2020 and December 31, 2019. At June 30, 2020 and December 31, 2019, the balance of the
borrowing from the credit agreement the Company entered into with
Mr. Grover in December 2018 was
approximately $4,518,000 and $4,085,000, respectively, net of debt
discounts. (See Note 6)
In July 2019, Mr. Grover acquired
600,242 shares of the Company's common stock upon the partial
exercise at $4.60 per share of a 2014 warrant to purchase 782,608 shares of
common stock held by him. In connection with such exercise, the
Company received approximately $2,761,000 from Mr. Grover, issued
to Mr. Grover 50,000 shares of restricted common stock as an
inducement fee and agreed to extend the expiration date of the
July 2014 warrant held by him to
December 15, 2020, and the exercise
price of the warrant was adjusted to $4.75 with respect to 182,366
shares of common stock remaining for exercise thereunder.
Paul Sallwasser
Mr. Paul Sallwasser is a member of the board directors, and prior
to joining the Company’s board of directors he acquired in the
Company’s 2014 private placement a
note in the principal amount of $75,000 convertible into 10,714
shares of common stock and a warrant exercisable for 14,673 shares
of common stock. Mr. Sallwasser additionally acquired in the
Company’s 2017 private placement a
note in the principal amount of $38,000 convertible into 8,177
shares of common stock and a warrant issued to purchase 5,719
shares of common stock. Mr. Sallwasser also acquired, as part of
the 2017 private placement in
exchange for the 2015 note that he
acquired in the Company’s 2015
private placement, an additional 2017 note in the principal amount of $5,000
convertible into 1,087 shares of common stock and a 2017 warrant exercisable for 543 shares of
common stock.
In March 2018, the Company
completed its Series B offering and in accordance with the terms of
the 2017 notes, Mr. Sallwasser’s
2017 notes converted to 9,264
shares of the Company’s common stock. Mr. Sallwasser’s 2017 warrants of to purchase an aggregate
6,262 shares of common stock expire between July and August during 2020.
In August 2019, Mr. Sallwasser
acquired 14,673 shares of the Company’s common stock upon the
exercise of his 2014 warrant. In
connection with the exercise, Mr. Sallwasser applied approximately
$67,000 of the proceeds of his 2014
note due to him from the Company as consideration for the warrant
exercise. The warrant exercise proceeds to the Company would have
been approximately $67,000. The Company paid the balance owed to
him under his 2014 note including
accrued interest of approximately $8,000.
At June 30, 2020 and 2019, Mr. Sallwasser owned 76,924 shares of
common stock and options to purchase an aggregate of 116,655 shares
of common stock, which are exercisable.
Daniel Mangless
Daniel Mangless became a beneficial owner of in excess of
5% of the Company’s outstanding
common stock upon consummation of a securities purchase agreement
transaction in March 2020.
In February 2019, the Company
entered into a securities purchase agreement with Mr. Mangless
pursuant to which the Company sold 250,000 shares of common stock
at an offering price of $7.00 per share. Pursuant to the purchase
agreement, the Company also issued Mr. Mangless a three-year warrant to purchase
250,000 shares of common stock at an exercise price of $7.00. The
Company received proceeds of $1,750,000 from the stock offering.
(See Note 10)
In June 2019, the Company entered
into a second securities purchase
agreement with Mr. Mangless pursuant to which the Company sold
250,000 shares of common stock at an offering price of $5.50 per
share. The Company received proceeds of $1,375,000 from the stock
offering. (See Note 10)
In March 2020, the Company entered
into a securities purchase agreement with Mr. Mangless, pursuant to
which the Company issued a senior secured promissory note in the
principal amount of $1,000,000 which matured in December 2020. In addition, the Company
issued 50,000 shares of common stock in connection with this senior
secured promissory note. (See Note 6 and 10)
In February 2021, Mr. Mangless
liquated some of his Youngevity common stock and is no longer a beneficial owner of in excess of
5% of the outstanding shares of
common stock. (See Note 13)
In April 2021, the Company entered
into a settlement agreement with Mr. Mangless related to the
payment schedule of the senior secured promissory note issued in
March 2020. In addition, as part of
the settlement agreement the Company issued Mr. Mangless 1,000,000
shares of common stock. (See Note 13)
2400 Boswell LLC
2400 Boswell is the owner and
lessor of the building occupied by the Company for its corporate
office and warehouse in Chula Vista, California. The Company
acquired 2400 Boswell from an
immediate member of the Company’s Chief Executive Officer in
2013. (See Note 6)
JJL Equipment Holding, LLC
In connection with the acquisition of Khrysos Global, the Company
held a deposit from JJL Equipment Holding, LLC (“JJL Equipment”)
for an equipment purchase of approximately $230,000 and $233,000 on
June 30, 2020 and December 31, 2019, respectively. Leigh
Dundore is a member and part owner of JJL Equipment. The deposit is
to be applied to future machinery and equipment orders from JJL
Equipment and was recorded in other current liabilities in the
consolidated balance sheet.
Youngevity Be the Change Foundation
Youngevity Be the Change Foundation (the “Youngevity Foundation”)
was formed in 2013 as a 501 c 3
charitable organization. The Company’s Chief Executive Officer and
its President and Chief Investment Officer both serve as officers
and directors of the Youngevity Foundation, as well as the
Company’s Chief Operating Officer and the wife of the Chief
Investment Officer who both serve as a director of the Youngevity
Foundation. During the three months
ended June 30, 2020 and 2019, the Company contributed approximately
$46,000 and $38,000, respectively, and $70,000 and $58,000,
respectively, for the six months
then ended. At June 30, 2020 and
December 31, 2019, the liability
representing future contributions to be made to the Youngevity
Foundation by the Company was $425,000 and $357,000, respectively,
and was included in current liabilities on the Company’s
consolidated balance sheets.
Daniel Briskie and Maida Briskie
Daniel Briskie and Maida Briskie, the father and mother of the
Company’s Chief Investment Officer, entered into note purchase
agreements in the principal amount of $25,000 in September 2014 related to the Company’s
private placement offering in 2014. In September 2019, the Company entered into an
agreement with Daniel Briskie and Maida Briskie to extend the
maturity date of their 2014 PIPE
Note for one year. At June 30, 2020 and December 31, 2019, the balance of the loan
was $25,000. (See Note 7).
Douglas Briskie
Douglas Briskie, the brother of the Company’s Chief Investment
Officer, entered into note purchase agreements in the principal
amount of $50,000 in August 2014
related to the Company’s private placement offering in 2014. The note was paid in full in
August 2019. (See Note 7).
Note 4. Revenue
Recognition
The following table summarizes disaggregated revenue by segment (in
thousands):
|
|
Three Months Ended
June 30,
|
|
|
Six Months Ended
June 30,
|
|
|
|
2020
|
|
|
2019
|
|
|
2020
|
|
|
2019
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
|
(unaudited) |
|
|
(unaudited) |
|
Direct selling
|
|
$ |
30,275 |
|
|
$ |
32,124 |
|
|
$ |
61,431 |
|
|
$ |
65,544 |
|
Processed green coffee
|
|
|
- |
|
|
|
968 |
|
|
|
519 |
|
|
|
1,068 |
|
Milling and processing services
|
|
|
156 |
|
|
|
1,561 |
|
|
|
324 |
|
|
|
6,387 |
|
Roasted coffee and other
|
|
|
2,078 |
|
|
|
3,290 |
|
|
|
5,450 |
|
|
|
6,069 |
|
Commercial coffee
|
|
|
2,234 |
|
|
|
5,819 |
|
|
|
6,293 |
|
|
|
13,524 |
|
Commercial hemp
|
|
|
483 |
|
|
|
274 |
|
|
|
799 |
|
|
|
341 |
|
Total revenue
|
|
$ |
32,992 |
|
|
$ |
38,217 |
|
|
$ |
68,523 |
|
|
$ |
79,409 |
|
Contract Balances
As of June 30, 2020 and December 31, 2019, deferred revenues were
approximately $7,249,000 and $3,569,000, respectively. Deferred
revenues in the direct selling segment related to customer deposits
were $1,375,000 and $1,626,000 on June
30, 2020 and December 31,
2019, respectively. Deferred revenues related to the rewards
program in the direct selling segment that began at the beginning
of 2020 were $1,705,000 at
June 30, 2020. Deferred revenues in
the direct selling segment related to Heritage Makers were
$1,648,000 and $1,795,000 at June 30,
2020, and December 31, 2019,
respectively. Deferred revenues related to pre-enrollment in
upcoming conventions were $158,000 and $148,000 at June 30, 2020, and December 31, 2019, respectively.
Deferred revenues in the commercial coffee segment related to
customer deposits were $2,363,000 at June 30, 2020. The commercial coffee segment
did not have a
deferred revenue balance on December 31,
2019.
The commercial hemp segment did not have a deferred
revenue balance on June 30, 2020 or
December 31, 2019.
The following table summarizes the classification of deferred
revenues balances on the balance sheets (in thousands):
|
|
June 30,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited)
|
|
|
|
|
|
Deferred revenue
|
|
$ |
5,447 |
|
|
$ |
1,943 |
|
Other current liabilities
|
|
|
1,375 |
|
|
|
1,626 |
|
Deferred revenue, current portion
|
|
|
6,822 |
|
|
|
3,569 |
|
Other long-term liabilities
|
|
|
427 |
|
|
|
- |
|
Deferred revenue, total
|
|
$ |
7,249 |
|
|
$ |
3,569 |
|
Of the deferred revenue at December 31,
2019, the Company recognized revenue of approximately $282,000
and $651,000 from the Heritage Makers product line during the
three and six months ended June 30, 2020, respectively.
At June 30, 2020 and December 31, 2019, the balance in deferred
costs related to prepaid commissions from Heritage Makers was
approximately $265,000 and $254,000, respectively.
Note 5. Selected Consolidated
Balance Sheet Information
Accounts Receivable, net
Net accounts receivable consists of the following (in
thousands):
|
|
June 30,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
Accounts receivable
|
|
$ |
10,662 |
|
|
$ |
11,142 |
|
Allowance for doubtful accounts
|
|
|
(8,210 |
)
|
|
|
(8,240 |
)
|
Accounts receivable, net
|
|
$ |
2,452 |
|
|
$ |
2,902 |
|
On June 30, 2020 and December 31, 2019, CLR’s accounts receivable
balance for customer related revenue by H&H Export was
approximately $8,707,000 of which the full amount was past due at
the respective periods. As a result, the Company reserved
$7,871,000 as bad debt related to the accounts receivable balances
for both periods, which was net of collections through December 31, 2020.
Inventory, net
Inventories consist of the following (in thousands):
|
|
June 30,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
Finished goods
|
|
$ |
13,049 |
|
|
$ |
14,890 |
|
Raw materials
|
|
|
13,488 |
|
|
|
11,694 |
|
Total inventory
|
|
|
26,537 |
|
|
|
26,584 |
|
Reserve for excess and obsolete
|
|
|
(3,555 |
)
|
|
|
(3,878 |
)
|
Inventory, net
|
|
$ |
22,982 |
|
|
$ |
22,706 |
|
Property and Equipment, net
Property and equipment consist of the following (in thousands):
|
|
June 30,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
Buildings
|
|
$ |
4,204 |
|
|
$ |
4,789 |
|
Leasehold improvements
|
|
|
3,114 |
|
|
|
2,948 |
|
Land
|
|
|
2,544 |
|
|
|
3,307 |
|
Land improvements
|
|
|
606 |
|
|
|
606 |
|
Producing coffee trees
|
|
|
553 |
|
|
|
553 |
|
Manufacturing equipment
|
|
|
10,462 |
|
|
|
9,568 |
|
Furniture and other equipment
|
|
|
2,062 |
|
|
|
2,050 |
|
Computer software
|
|
|
1,442 |
|
|
|
1,420 |
|
Computer equipment
|
|
|
2,714 |
|
|
|
2,648 |
|
Vehicles
|
|
|
326 |
|
|
|
326 |
|
Assets held for sale (1)
|
|
|
1,496 |
|
|
|
- |
|
Construction in process
|
|
|
7,619 |
|
|
|
6,562 |
|
Total property and equipment, gross
|
|
|
37,142 |
|
|
|
34,777 |
|
Accumulated depreciation
|
|
|
(12,791 |
)
|
|
|
(11,461 |
)
|
Total property and equipment, net
|
|
$ |
24,351 |
|
|
$ |
23,316 |
|
(1)
|
Assets held for sale at June 30,
2020 consisted of approximately $1,053,000 in land and
$443,000 in buildings related to the commercial hemp segment. (See
Note 13)
|
Depreciation expense totaled approximately $660,000 and $602,000
for the three months ended
June 30, 2020 and 2019, respectively, and $1,333,000 and
$1,077,000 for the respective six
month periods.
Operating and Financing Leases
The Company’s operating and financing lease assets and liabilities
recognized within its consolidated balance sheets were classified
as follows (in thousands):
|
|
June 30,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Operating lease right-of-use assets
|
|
$ |
7,325 |
|
|
$ |
8,386 |
|
Finance lease right-of-use assets (1)
|
|
|
1,104 |
|
|
|
1,052 |
|
Total leased assets
|
|
$ |
8,429 |
|
|
$ |
9,438 |
|
Liabilities
|
|
|
|
|
|
|
|
|
Operating lease liabilities, current portion
|
|
$ |
1,584 |
|
|
$ |
1,740 |
|
Finance lease liabilities, current portion
|
|
|
856 |
|
|
|
736 |
|
Total leased liabilities, current portion
|
|
|
2,440 |
|
|
|
2,476 |
|
Operating lease liabilities, net of current portion
|
|
|
5,928 |
|
|
|
6,646 |
|
Finance lease liabilities, net of current portion
|
|
|
314 |
|
|
|
408 |
|
Total lease liabilities
|
|
$ |
8,682 |
|
|
$ |
9,530 |
|
(1)
|
Finance lease right-of-use assets are recorded within property and
equipment, net of accumulated amortization of approximately
$1,759,000 and $1,367,000 at June 30,
2020 and December 31, 2019,
respectively
|
The weighted-average remaining lease term and weighted-average
discount rate used to calculate the present value of lease
liabilities are as follows:
|
|
June 30,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited)
|
|
|
|
|
|
Weighted-average remaining lease term (in years)
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
6.8 |
|
|
|
6.8 |
|
Finance leases
|
|
|
1.4 |
|
|
|
1.6 |
|
Weighted-average discount rate
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
5.42 |
%
|
|
|
5.47 |
%
|
Finance leases
|
|
|
4.80 |
%
|
|
|
4.57 |
%
|
Operating and finance lease costs were as follows (in
thousands):
|
|
Three Months Ended
|
|
|
Six Months
Ended
|
|
|
|
June 30,
|
|
|
June 30,
|
|
|
|
2020
|
|
|
2019
|
|
|
2020
|
|
|
2019
|
|
|
|
(unaudited)
|
|
|
(unaudited) |
|
|
(unaudited)
|
|
|
(unaudited) |
|
Operating lease cost (1)
|
|
$ |
546 |
|
|
$ |
271 |
|
|
$ |
1,096 |
|
|
$ |
542 |
|
Finance lease cost:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of leased assets (2)
|
|
|
211 |
|
|
|
94 |
|
|
|
392 |
|
|
|
190 |
|
Interest on lease liabilities (3)
|
|
|
24 |
|
|
|
34 |
|
|
|
48 |
|
|
|
71 |
|
Total operating and finance lease cost
|
|
$ |
781 |
|
|
$ |
399 |
|
|
$ |
1,536 |
|
|
$ |
803 |
|
(1)
|
Operating lease costs are classified within selling and marketing
and general and administrative expenses.
|
(2)
|
Amortization of leased assets are classified as a component of
depreciation and amortization.
|
(3)
|
Interest on lease liabilities are classified within interest
expense, net.
|
Intangible Assets
Intangible assets consist of the following (in thousands):
|
|
June 30, 2020
(unaudited)
|
|
|
December 31, 2019
|
|
|
|
Cost
|
|
|
Accumulated
Amortization
|
|
|
Net
|
|
|
Cost
|
|
|
Accumulated
Amortization
|
|
|
Net
|
|
Distributor organizations
|
|
$ |
15,735 |
|
|
$ |
10,870 |
|
|
$ |
4,865 |
|
|
$ |
15,735 |
|
|
$ |
10,418 |
|
|
$ |
5,317 |
|
Trademarks and trade names
|
|
|
8,430 |
|
|
|
2,893 |
|
|
|
5,537 |
|
|
|
8,430 |
|
|
|
2,539 |
|
|
|
5,891 |
|
Customer relationships
|
|
|
10,442 |
|
|
|
6,761 |
|
|
|
3,681 |
|
|
|
10,442 |
|
|
|
6,413 |
|
|
|
4,029 |
|
Internally developed software
|
|
|
720 |
|
|
|
708 |
|
|
|
12 |
|
|
|
720 |
|
|
|
657 |
|
|
|
63 |
|
Non-compete agreement
|
|
|
277 |
|
|
|
46 |
|
|
|
231 |
|
|
|
277 |
|
|
|
11 |
|
|
|
266 |
|
Intangible assets
|
|
$ |
35,604 |
|
|
$ |
21,278 |
|
|
$ |
14,326 |
|
|
$ |
35,604 |
|
|
$ |
20,038 |
|
|
$ |
15,566 |
|
Amortization expense related to intangible assets was approximately
$620,000 and $586,000 for the three
months ended June 30, 2020 and
2019, respectively. Amortization
expense related to intangible assets was approximately $1,240,000
and $1,256,000 for the six months
ended June 30, 2020 and 2019, respectively.
At June 30, 2020 and December 31, 2019, approximately $1,649,000
in trademarks from business combinations have been identified as
having indefinite lives.
Goodwill
Goodwill by segment consists of the following (in thousands):
|
|
June 30,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited)
|
|
|
|
|
|
Direct selling
|
|
$ |
3,678 |
|
|
$ |
3,678 |
|
Commercial coffee
|
|
|
3,314 |
|
|
|
3,314 |
|
Commercial hemp
|
|
|
- |
|
|
|
- |
|
Total goodwill
|
|
$ |
6,992 |
|
|
$ |
6,992 |
|
Note 6. Notes
Payable and Other Debt
Credit Note
In December 2018, CLR entered into
a credit agreement with Mr. Grover pursuant to which CLR borrowed
$5,000,000 from Mr. Grover and in exchange issued to him a
$5,000,000 credit note (the “Credit Note”). In addition, Siles, as
guarantor, executed a separate guaranty agreement. The Credit Note
is secured by CLR’s green coffee inventory, subordinate to certain
debt owed to Crestmark Bank and pari passu with certain holders of
notes issued by the borrowers of the company in 2014. At both June
30, 2020 and December 31,
2019, the outstanding principal balance of the Credit Note was
$5,000,000.
The Credit Note accrues interest at a rate of 8.00% per annum and
in accordance with the Credit Note is paid quarterly. The credit
note contains customary events of default including the Company or
Siles failure to pay its obligations, commencing bankruptcy or
liquidation proceedings, and breach of representations and
warranties. Upon the occurrence of an event of default, the unpaid
balance of the principal amount of the Credit Note together with
all accrued but unpaid interest thereon, may become, or may be declared to be, due and payable by Mr.
Grover and shall bear interest from the due date until such amounts
are paid at the rate of 10.00% per annum. In connection with the
credit agreement, the Company issued to Mr. Grover a four-year warrant to purchase
250,000 shares of its common stock, exercisable at $6.82 per share,
and a four-year
warrant to purchase 250,000 shares of its common stock, exercisable
at $7.82 per share.
In connection with the Credit Note, the Company also entered into
an advisory agreement with a third
party not affiliated with Mr.
Grover, pursuant to which the Company agreed to pay to the advisor
a 3.00% fee on the transaction with Mr. Grover and issued to the
advisor’s designee a four-year warrant to purchase
50,000 shares of the Company’s common stock, exercisable at $6.33
per share.
The Company recorded debt discounts of approximately $1,469,000
related to the fair value of warrants issued in the transaction and
$175,000 of transaction issuance costs both of which are amortized
to interest expense over the life of the Credit Note. The Company
recorded amortization of approximately $224,000 and $167,000
related to the debt discount and issuance cost during the
three months ended June 30, 2020 and 2019, respectively, and $433,000 and $321,000
during the six months ended
June 30, 2020 and 2019, respectively. At June 30, 2020 and December 31, 2019, the combined remaining
balance of the debt discounts and issuance cost was approximately
$482,000 and $915,000, respectively.
In December 2020, the Credit Note
became payable and due in accordance with its terms. CLR did
not make the payment due upon the
maturity date of the Credit Note. At the filing date of this
Quarterly Report on Form 10-Q, the
Company was in default of the terms of settlement of the Credit
Note and the Credit Note remains outstanding; however no formal demand for repayment has been
made.
2019 Promissory
Notes
In March 2019, the Company entered
into a two-year
secured promissory note (the “2019
Promissory Notes”) with two
accredited investors that had a substantial pre-existing
relationship with the Company pursuant to which the Company raised
cash proceeds in the aggregate of $2,000,000. The 2019 Promissory Notes bear interest at a rate
of 8.00% per annum and interest is paid quarterly in arrears with
all principal and unpaid interest due at maturity on March 18, 2021. The 2019 Promissory Notes are secured by all
equity in KII. At both June 30,
2020 and December 31, 2019,
the outstanding principal balance of the 2019 Promissory Notes was $2,000,000.
In conjunction with the 2019
Promissory Notes, the Company also issued 40,000 shares of the
Company’s common stock and five-year warrants to purchase
40,000 shares of the Company’s common stock. (See Note 10)
The Company recorded debt discounts of approximately $212,000
related to transaction issuance costs and $139,000 related to the
fair value of warrants issued in the transaction both of which are
amortized to interest expense over the life of the 2019 Promissory Notes. The Company recorded
amortization of approximately $45,000 and $37,000 related to the
debt discount and issuance cost related to the promissory notes
during the three months ended
June 30, 2020 and 2019, respectively and $88,000 and $42,000
during the six months ended
June 30, 2020 and 2019, respectively. At June 30, 2020 and December 31, 2019, the combined remaining
balance of the debt discount and issuance costs was approximately
$140,000 and $228,000, respectively.
In February 2021, the Company
entered into amendment agreements extending the 2019 Promissory Notes and increasing the
interest rate. At the filing date, the Company was in default of
the terms of the amended agreements. (See Note 13)
Mangless Note
In March 2020, the Company entered
into a securities purchase agreement with Daniel Mangless pursuant
to which the Company issued a senior secured promissory note in the
principal amount of $1,000,000 (the “Mangless Note”) which matured
in December 2020, bearing interest
at 18.00% per annum. In December
2020, the Company defaulted on the settlement of the Mangless
Note.
The Mangless Note provided the Company with an option to prepay at
any time without permission or penalty. The Mangless Note is
secured pursuant to the terms of a pledge and security agreement,
entered into by the Company and CLR with Mr. Mangless, whereby the
Mangless Note is secured by a first
priority lien granted by CLR in its rights under the pledge and
security agreement, by and between H&H, H&H Export and CLR
to receive certain payments (the “Mangless Pledge and Security
Agreement”).
In addition, the Company issued 50,000 shares of common stock in
connection with Mangless Note. (See Note 10)
The Company recognized debt discounts of approximately $65,000
resulting from the allocated portion of offering proceeds to the
separable common stock issuance. The debt discount was amortized to
interest expense over the term of the Mangless Note. The Company
recorded amortization of approximately $16,000 and $18,000 related
to the debt discount during the three and six
months ended June 30, 2020,
respectively. At June 30, 2020, the
remaining balance of the debt discounts was approximately
$47,000.
In April 2021, the Company entered
into a settlement agreement with Mr. Mangless related to the
payment schedule of the Mangless Note issued in March 2020. In addition, as part of the
settlement agreement the Company issued Mr. Mangless 1,000,000
shares of common stock. (See Note 13)
2400 Boswell Mortgage
Note
In connection with the acquisition of 2400 Boswell, LLC in 2013, the Company assumed a mortgage of
$3,625,000, payable over 25 years. The Company and its Chief
Executive Officer and Chairman and Chief Operating Officer are
guarantors of the mortgage. Interest is paid monthly at the prime
rate plus 2.50% and is adjusted by the lender on the first calendar day of month. At June 30, 2020 and December 31, 2019, the interest rate was
5.75% and 7.50%, respectively. At June
30, 2020 and December 31,
2019, the outstanding principal balance on the mortgage was
approximately $3,107,000 and $3,143,000, respectively.
The Company’s corporate office’s mortgage qualified for the
mortgage payment program for a period of six months under the Small Business
Administration (“SBA”) lenders program as described below.
Khrysos Mortgage Notes
In conjunction with the Company’s acquisition of Khrysos Global,
the Company assumed an interest only mortgage for properties
located in Mascotte, Florida in the amount of $350,000 and interest
paid monthly at a rate of 8.00% per annum. In September 2021, the mortgage was amended to
extend the maturity date by one
year to the earlier of September
2022 or the date of the sale of the property.
In addition, the Company assumed a mortgage of approximately
$177,000 for properties located in Clermont, Florida with all
unpaid principal due in June 2023
and interest paid monthly at a rate of 7.00% per annum.
At June 30, 2020 and December 31, 2019, the aggregate outstanding
principal balance on the mortgages was approximately $518,000 and
$528,000, respectively.
In February 2019, KII purchased a
45-acre tract of land in Groveland, Florida for $750,000. The
Company paid $300,000 as a down payment and assumed a mortgage of
$450,000. All unpaid principal was due in February 2024 and interest was paid monthly
at a rate of 6.00% per annum. At June
30, 2020 and December 31,
2019, the remaining mortgage balance was approximately
$434,000 and $440,000, respectively.
In February 2021, the Company
determined that KII’s original plan for use of certain properties
was not viable for its future as
KII had shifted its focus back to its primary core business of
extraction of cannabinoids and the production of products for sale
with the cannabinoids. As a result, the Khrysos Mortgage Notes were
subsequently sold. (See Note 13)
M2C Purchase
Agreement
In March 2007, the Company entered
into an agreement to purchase certain assets of M2C Global, Inc., a Nevada corporation, for
$4,500,000. The agreement required payments totaling $500,000
in three installments during 2007,
followed by monthly payments in the amount of 10.00% of the sales
related to the acquired assets until the entire note balance is
paid. At June 30, 2020 and
December 31, 2019, the carrying
value of the liability was approximately $1,006,000 and $1,027,000,
respectively.
Small Business Administration – Paycheck
Protection Program Loans
In April 2020, the Company’s
three segments participated in “The
Coronavirus Aid, Relief, and Economic Security Act and the Paycheck
Protection Program due to losses caused by the COVID-19 pandemic. In April 2020, the Company received cash in the
aggregate of approximately $3,763,000 from qualified Small Business
Administration (“SBA”) lenders. Under the SBA loans, the Company
received $2,508,000 related to its direct selling segment, $633,000
related to its commercial coffee segment and $623,000 related to
its commercial hemp segment.
The Company’s direct selling segment qualified for mortgage
assistance, whereby the Company’s corporate office’s mortgage had
been paid directly from the SBA lenders for a period of six months during 2020. During the three months ended June 30, 2020, the SBA paid approximately
$72,000 in principal and interest directly to the Company’s
mortgage holder.
In July 2020, the Company’s
commercial coffee segment received a second loan in the amount of $150,000 from
SBA lenders.
During the three months ended
September 30, 2020, the SBA paid
approximately $70,000 in principal and interest directly to the
Company’s mortgage holder related to mortgage assistance. In
November 2020, the SBA lenders
forgave approximately $613,000 in loan proceeds received in
April 2020. In April 2021, the Company’s commercial coffee
segment received a third loan in
the amount of approximately $633,000 from SBA lenders. In
June 2021, the SBA lenders forgave
approximately $3,141,000 which represented loan proceeds the
Company received in 2020. (See Note
13)
Other Notes
The Company’s other notes relate to loans for commercial vans at
CLR in the amount of $61,000 and $71,000 at June 30, 2020 and December 31, 2019, respectively, which expire
at various dates through 2023.
Line of Credit
The Company’s loan and security agreement with Crestmark Bank
(“Crestmark”) provides for a line of credit related to accounts
receivables resulting from sales of certain products that includes
borrowings to be advanced against acceptable eligible inventory
related to CLR. Under the loan and security agreement the maximum
overall borrowing limit on the line of credit is $6,250,000. The
line of credit may not exceed an amount which is the lesser of
(a) $6,250,000 or (b) the sum of up (i) to 85% of the value of the
eligible accounts; plus, (ii) the lesser of $1,000,000 or 50% of
eligible inventory or 50% of the amount calculated in (i) above,
plus (iii) the lesser of $250,000 or eligible inventory or 75% of
certain specific inventory identified within the agreement.
The agreement contains certain financial and nonfinancial covenants
with which the Company must comply to maintain its borrowing
availability and avoid penalties. At the filing date of this
Quarterly Report on Form 10-Q, the
Company was not in compliance with
the covenants under the terms of the agreement.
In January 2022, the Company
entered into the second amendment
to the Crestmark loan and security agreement which reduced the
maximum overall borrowing limit on the line of credit to
$3,000,000. In February 2022, the
Company received a notice of default related to the loan and
security agreement from Crestmark. In April 2022, The Company entered into a
forbearance agreement with Crestmark. (See Note 13)
The outstanding principal balance of the line of credit bears
interest based upon a 360-day year
with interest charged for each day the principal amount is
outstanding including the date of actual payment. The interest rate
is a rate equal to the prime rate plus 2.50% with a floor of 6.75%.
At June 30, 2020 and December 31, 2019, the interest rate was
6.75% and 7.25%, respectively. In addition, other fees are incurred
for the maintenance of the loan in accordance with the agreement.
Other fees may be incurred in the
event the minimum loan balance of $2,000,000 is not maintained. The agreement was effective
beginning in November 2017 and will
continue to be effective until June 30,
2022, the termination date agreed upon in the forbearance
agreement entered in April
2022.
The Company and Stephan Wallach entered into a corporate guaranty
and personal guaranty, respectively, with Crestmark guaranteeing
payments in the event that the Company’s commercial coffee segment
CLR were to default. In addition, David Briskie, the Company’s
president and chief financial officer, personally entered into a
guaranty of validity representing the Company’s financial
statements so long as the indebtedness is owed to Crestmark,
maintaining certain covenants and guarantees.
The Company’s outstanding line of credit liability with Crestmark
was approximately $1,499,000 and $2,011,000 at June 30, 2020 and December 31, 2019, respectively.
Note 7. Convertible Notes
Payable
Total convertible notes payable, net of debt discount outstanding
consisted of the amount set forth in the following table (in
thousands):
|
|
June 30,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited)
|
|
|
|
|
|
6.00% Convertible Notes
(2019 PIPE Notes), principal
|
|
$ |
3,090 |
|
|
$ |
3,090 |
|
Debt discounts
|
|
|
(247 |
)
|
|
|
(415 |
)
|
Carrying value of 2019 PIPE Notes
|
|
|
2,843 |
|
|
|
2,675 |
|
|
|
|
|
|
|
|
|
|
8.00% Convertible Notes
(2014 PIPE Notes), principal
|
|
|
25 |
|
|
|
25 |
|
Debt discounts
|
|
|
– |
|
|
|
– |
|
Carrying value of 2014 PIPE Notes
|
|
|
25 |